[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 94 of about 94
1. Chesnay E, Babin E, Constans JM, Agostini D, Bequignon A, Regeasse A, Sobrio F, Moreau S: Early response to chemotherapy in hypopharyngeal cancer: assessment with (11)C-methionine PET, correlation with morphologic response, and clinical outcome. J Nucl Med; 2003 Apr;44(4):526-32
Hazardous Substances Data Bank. (L)-Methionine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early response to chemotherapy in hypopharyngeal cancer: assessment with (11)C-methionine PET, correlation with morphologic response, and clinical outcome.
  • Neoadjuvant chemotherapy in hypopharyngeal cancer globally improves survival, but some patients do not respond to chemotherapy and adjuvant therapy is delayed.
  • Prediction of response to chemotherapy may allow physicians to optimize planned treatment.
  • The aim of this study was to compare treatment response assessed early with (11)C-methionine PET and morphologic response assessed after treatment completion with MRI.
  • METHODS: Thirteen patients with previously untreated squamous cell carcinoma of the hypopharynx, T3 or T4, were included.
  • All patients received 3 courses of chemotherapy comprising cisplatin and 5-fluorouracil. (11)C-Methionine PET was performed before and after the first course of chemotherapy.
  • PET estimation of response was expressed in relative variation of mean standardized uptake value (SUVmean), maximal standardized uptake value (SUVmax), volume of (11)C-methionine tumor uptake, and total tumor uptake.
  • Posttreatment response was assessed with MRI, which was performed before the first course and after treatment completion, and expressed in relative variation of tumor volume.
  • Patients were considered responders if their tumor volume was reduced by more than 50%.
  • CONCLUSION: (11)C-Methionine PET provides early useful information about changes in tumor metabolism induced by chemotherapy in hypopharynx cancer. (11)C-Methionine PET measurements correlate with end-of-treatment response evaluated with MRI and may thus be helpful to physicians in treatment planning by avoiding unnecessary chemotherapy courses for nonresponding patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radionuclide imaging. Methionine. Tomography, Emission-Computed / methods
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / drug therapy. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity. Statistics as Topic. Treatment Outcome

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12679395.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 58576-49-1 / carbon-11 methionine; AE28F7PNPL / Methionine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Chang MF, Wang HM, Kang CJ, Huang SF, Lin CY, Fang KH, Chen EY, Chen IH, Liao CT, Chang JT: Treatment results for hypopharyngeal cancer by different treatment strategies and its secondary primary--an experience in Taiwan. Radiat Oncol; 2010;5:91
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results for hypopharyngeal cancer by different treatment strategies and its secondary primary--an experience in Taiwan.
  • PURPOSE: The aim of this study was to evaluate treatment results in our hypopharyngeal cancer patients.
  • PATIENTS AND METHODS: A total of three hundred and ninety five hypopharyngeal cancer patients received radical treatment at our hospital; 96% were male.
  • All patients received a CT scan or MRI for tumor staging before treatment.
  • Radical surgery was used first in 81 patients (20.5%), and the remaining patients (79.5%) received organ preservation-intended treatment (OPIT).
  • In the OPIT group, 46 patients received radiotherapy alone, 156 patients received chemotherapy followed by radiotherapy (CT/RT) and 112 patients received concomitant chemo-radiotherapy (CCRT).
  • Thirty-seven patients developed a second malignancy, with an annual incidence of 4.6%.
  • CONCLUSIONS: There was no survival difference between OPIT and radical surgery in hypopharyngeal cancer patients at our hospital.
  • Additionally, second primary cancers are another important issue for hypopharyngeal cancer management.
  • [MeSH-major] Hypopharyngeal Neoplasms / therapy. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Digestive System Surgical Procedures. Female. Humans. Incidence. Kaplan-Meier Estimate. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Staging. Radiotherapy. Taiwan. Tegafur / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6 [10601378.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1391-6 [20056352.001]
  • [Cites] Semin Surg Oncol. 2001 Jan-Feb;20(1):66-74 [11291134.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2001 Feb;26(1):59-61 [11298170.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2989-95 [12115388.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):733-8 [12874074.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):481-7 [15145166.001]
  • [Cites] Head Neck. 2004 Jul;26(7):561-72 [15229898.001]
  • [Cites] ANZ J Surg. 2004 Jul;74(7):554-8 [15230789.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2856-64 [15254053.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jul;130(7):861-7 [15262764.001]
  • [Cites] Onkologie. 2004 Aug;27(4):368-75 [15347892.001]
  • [Cites] Cancer Treat Rev. 1975 Sep;2(3):177-91 [1104162.001]
  • [Cites] Am J Surg. 1977 Oct;134(4):489-91 [911032.001]
  • [Cites] Cancer. 1983 May 15;51(10):1819-25 [6831347.001]
  • [Cites] Cancer. 1990 Apr 15;65(8):1685-91 [2317751.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Aug;122(8):853-7 [8703389.001]
  • [Cites] Head Neck. 1996 Sep-Oct;18(5):405-11 [8864731.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Feb;125(2):142-8 [10037279.001]
  • [Cites] Cancer. 1953 Sep;6(5):963-8 [13094644.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1425-39 [15590174.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):88-95 [15625363.001]
  • [Cites] Clin Otolaryngol. 2005 Feb;30(1):52-7 [15748191.001]
  • [Cites] Br J Cancer. 2005 Aug 8;93(3):279-86 [16012523.001]
  • [Cites] Br J Cancer. 2005 Nov 14;93(10):1117-21 [16251869.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1064-71 [16505425.001]
  • [Cites] Strahlenther Onkol. 2006 Jun;182(6):331-5 [16703288.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):459-68 [17493769.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • (PMID = 20925962.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin
  • [Other-IDs] NLM/ PMC2958972
  •  go-up   go-down


3. Krstevska V, Stojkovski I, Lukarski D: Concurrent radiochemotherapy in advanced hypopharyngeal cancer. Radiat Oncol; 2010;5:39
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent radiochemotherapy in advanced hypopharyngeal cancer.
  • Unfortunately, there is a lack of level one evidence on best treatment approach for advanced hypopharyngeal cancer.
  • This report aims to summarize the results of our study on concurrent radiochemotherapy in patients with advanced hypopharyngeal cancer.
  • METHODS: A retrospective analysis of 41 patients with stage III-IV hypopharyngeal cancer was performed.
  • All patients were treated with three dimensional conformal radiotherapy and received 70 Gy in 35 fractions (2 Gy per fraction, 5 fractions per week).
  • In dependence of the period when radiotherapy was realized, two different treatment techniques were used.
  • Concurrent chemotherapy consisted of cisplatin 30 mg/m2 given on a weekly basis.
  • Complete response rates at the primary site and at the metastatic neck lymph nodes were 68.3% and 36.6%, respectively.
  • Confluent mucositis was developed in 46.3% of patients.
  • The median weight loss at the end of treatment was 12% (range 5-21).
  • The worst grade of late toxicity was most commonly pronounced in the skin and in the subcutaneous tissue.
  • CONCLUSIONS: Based on unsatisfactory results in our study we suggest that the use of sequential radiochemotherapy or chemotherapy given concomitantly with altered fractionation radiotherapy with the implementation of intensity-modulated radiotherapy as radiotherapy technique could represent treatment approaches able to improve outcome in patients with advanced hypopharyngeal cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Radiotherapy, Conformal
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1458-64 [10735893.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Sep;124(9):951-62 [9738803.001]
  • [Cites] Radiother Oncol. 2000 May;55(2):101-10 [10799721.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16 [10924966.001]
  • [Cites] Acta Oncol. 2000;39(4):529-36 [11041117.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2001 Feb;26(1):59-61 [11298170.001]
  • [Cites] Head Neck. 2001 Sep;23(9):713-7 [11505479.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2002 Oct;27(5):413-20 [12383309.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):320-6 [12525525.001]
  • [Cites] Lancet. 2003 Sep 20;362(9388):933-40 [14511925.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3540-8 [15337803.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Cancer. 1983 May 15;51(10):1819-25 [6831347.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Mar;11(3):499-504 [3972662.001]
  • [Cites] Laryngoscope. 1987 Aug;97(8 Pt 1):901-4 [3613786.001]
  • [Cites] Head Neck. 1993 Sep-Oct;15(5):405-12 [8407312.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6 [7713792.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4665-73 [15534360.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):88-95 [15625363.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1125-35 [15718308.001]
  • [Cites] Clin Otolaryngol. 2005 Feb;30(1):52-7 [15748191.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] BMC Cancer. 2006;6:28 [16448551.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1064-71 [16505425.001]
  • [Cites] Lancet. 2006 Sep 2;368(9538):843-54 [16950362.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):459-68 [17493769.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):156-70 [17482300.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):7-16 [17920715.001]
  • [Cites] Acta Otolaryngol. 2008 May;128(5):590-6 [18421617.001]
  • [Cites] Jpn J Clin Oncol. 2008 Aug;38(8):521-7 [18697758.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1143-54 [18784104.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 4;101(3):142-52 [19176454.001]
  • [Cites] Acta Oncol. 2009;48(4):541-48 [18979267.001]
  • [Cites] Head Neck. 2009 Jun;31(6):748-58 [19189340.001]
  • [Cites] Radiother Oncol. 2009 Jul;92(1):4-14 [19446902.001]
  • [Cites] Cancer. 2009 Dec 15;115(24):5711-22 [19708030.001]
  • [Cites] Lancet Oncol. 2010 Jan;11(1):21-8 [19897418.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1995 Jun;20(3):249-53 [7554339.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] Laryngoscope. 1997 May;107(5):648-53 [9149168.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1318-24 [9552032.001]
  • [Cites] N Engl J Med. 1998 Jun 18;338(25):1798-804 [9632446.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • (PMID = 20482772.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2890021
  •  go-up   go-down


Advertisement
4. Quer M, León X: [Organ preservation in laryngeal and hypopharyngeal cancer]. Acta Otorrinolaringol Esp; 2007 Dec;58(10):476-82
Genetic Alliance. consumer health - Laryngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Organ preservation in laryngeal and hypopharyngeal cancer].
  • [Transliterated title] Modalidades de preservación de órgano en carcinomas de laringe e hipofaringe.
  • Organ preservation in advanced laryngeal and hypopharyngeal squamous cell carcinoma has been a major target for clinical research in the last years.
  • For a long time, partial surgery and radiotherapy were the only options that could preserve the larynx.
  • Partial surgery has developed new open techniques and, with the introduction of laser it continues to have a clear role in organ preservation.
  • But, the real revolution began after 1980 with the introduction of chemotherapy that increased the options.
  • Induction chemotherapy followed by radiotherapy where response is good has allowed the larynx to be preserved in about half of the cases, without jeopardizing survival.
  • Concomitant chemoradiotherapy gives better results in preservation, and induction chemotherapy followed by concomitant chemoradiotherapy is under clinical research.
  • Finally, new targeted treatments open up new fields in clinical research.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / surgery. Hypopharyngeal Neoplasms / epidemiology. Hypopharyngeal Neoplasms / surgery. Laryngeal Neoplasms / epidemiology. Laryngeal Neoplasms / surgery. Salvage Therapy / statistics & numerical data
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging. Postoperative Period

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18082078.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 61
  •  go-up   go-down


5. Divi V, Worden FP, Prince ME, Eisbruch A, Lee JS, Bradford CR, Chepeha DB, Teknos TN, Hogikyan ND, Moyer JS, Tsien CI, Urba SG, Wolf GT: Chemotherapy alone for organ preservation in advanced laryngeal cancer. Head Neck; 2010 Aug;32(8):1040-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy alone for organ preservation in advanced laryngeal cancer.
  • BACKGROUND: For patients with advanced laryngeal cancer, a trial was designed to determine if chemotherapy alone, in patients achieving a complete histologic complete response after a single neoadjuvant cycle, was an effective treatment with less morbidity than concurrent chemoradiotherapy.
  • METHODS: Thirty-two patients with advanced laryngeal or hypopharyngeal cancer received 1 cycle of induction chemotherapy, and subsequent treatment was decided based on response.
  • RESULTS: A histologic complete response was achieved in 4 patients and were treated with chemotherapy alone.
  • All 4 patients' cancer relapsed in the neck and required surgery and postoperative radiotherapy (RT).
  • CONCLUSION: Chemotherapy alone is not feasible for long-term control of regional disease in patients with advanced laryngeal cancer even when they achieve a histologic complete response at the primary site.

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Wiley Periodicals, Inc. Head Neck, 2010.
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1504-11 [11745228.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] J Clin Oncol. 2009 Apr 20;27(12):1976-82 [19289628.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):593-8 [16380415.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S79-82 [17848301.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2331-6 [8708725.001]
  • (PMID = 19953609.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA097248-06A1; United States / NCI NIH HHS / CA / P50 CA97248; United States / NIDCD NIH HHS / DC / P30 DC 05188; United States / NCI NIH HHS / CA / P50 CA097248; United States / NIDCR NIH HHS / DE / R01 DE013346; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / P30 CA46592; United States / NIDCD NIH HHS / DC / P30 DC005188; United States / NCI NIH HHS / CA / P50 CA097248-06A1; United States / NIDCR NIH HHS / DE / R01 DE13346
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS150154; NLM/ PMC2891819
  •  go-up   go-down


6. Yu F, Dong YL, Zu ZJ, Zhan XD, Shu JH, Yang JS, Han GS, Lu LC, Zhang K, Sun HJ, Ren KJ: [Surgical management of hypopharyngeal cancer]. Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Aug;38(4):295-9
Genetic Alliance. consumer health - Hypopharyngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical management of hypopharyngeal cancer].
  • OBJECTIVE: To investigate the preservation of laryngeal function for the patients with hypopharyngeal cancer.
  • METHODS: Two hundred and ninety-three cases of hypopharyngeal cancer with surgical management were reviewed retrospectively, and 222 cases were originated from pyriform sinus, 13 from post-cricoid, and 21 from posterior pharyngeal wall.
  • Radiotherapy (37 cases), operation only (56 cases) and the combined treatment (operation plus radiation or chemotherapy, 200 cases) were adopted.
  • The analysis of survival rates revealed a significant difference between combined therapy and radiotherapy.
  • CONCLUSION: There is no significant difference between the survive rates of function preserved and non-preserved groups.
  • Conservation laryngectomy improves the quality of patient's life, and combined therapy is the best choice for hypopharyngeal cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Hypopharyngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Laryngectomy. Larynx / physiopathology. Larynx / surgery. Male. Middle Aged. Quality of Life. Reconstructive Surgical Procedures. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14743643.001).
  • [ISSN] 0412-3948
  • [Journal-full-title] Zhonghua er bi yan hou ke za zhi
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


7. Kohno N: The role of chemotherapy for advanced oro and hypopharyngeal cancer. Auris Nasus Larynx; 2004 Jun;31(2):113-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of chemotherapy for advanced oro and hypopharyngeal cancer.
  • Although important progress continuous to be made in the treatment of oro and hypopharyngeal cancer, the 5-year survival rate for all this disease has remained at less than 30% for the past 30 years.
  • In the early 1980s, chemotherapy was introduced with high expectation of reducing in the incidence of distant metastases and increasing the possibility of local control.
  • This article explores the use of chemotherapy in the treatment of advanced pharyngeal cancer.
  • Thus, the efficacy of chemotherapy are reviewed and treatment options for advanced pharyngeal cancer are made.
  • In these cases, the possibility of instituting adjuvant chemotherapy with an active treatment regimen may be taken into account depending on the condition of the patient and the tumor.
  • Patients with surgically resectable tumors are given 1-2 cycles of induction chemotherapy.
  • Cases who respond to the induction chemotherapy are subsequently given concurrent chemoradiotherapy.
  • The cases who do not respond to the induction chemotherapy are treated with radical surgery.
  • Patients with unresectable carcinoma are given concurrent chemoradiotherapy because local treatment should be performed in such patients as early as possible.
  • In principle, concurrent regimens should be supplemented with adjuvant chemotherapy in all cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15121218.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 35
  •  go-up   go-down


8. Kusuki M, Iguchi H, Nakamura A, Nishiura H, Kanazawa A, Yamane H: The syndrome of inappropriate antidiuretic hormone secretion associated with chemotherapy for hypopharyngeal cancer. Acta Otolaryngol Suppl; 2004 Oct;(554):74-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The syndrome of inappropriate antidiuretic hormone secretion associated with chemotherapy for hypopharyngeal cancer.
  • It has been reported that SIADH may occur due to various factors in patients with malignant tumor.
  • We report a case of hypopharyngeal cancer complicated by SIADH following chemotherapy.
  • A 72-year-old woman with hypopharyngeal cancer was treated by oral administration of S-1 and intravenous administration of low-dose cisplatin following radiation therapy.
  • General fatigue and coma occurred during the third course of this chemotherapy, using S-1 and low-dose cisplatin.
  • Unfortunately, her hypopharyngeal cancer gradually progressed and she died of acute pneumonia three months later.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoma, Squamous Cell / complications. Cisplatin / adverse effects. Hypopharyngeal Neoplasms / complications. Inappropriate ADH Syndrome / chemically induced
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / therapeutic use. Drug Combinations. Fatal Outcome. Female. Humans. Hyponatremia / blood. Osmolar Concentration. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Radiotherapy, Adjuvant. Tegafur / therapeutic use. Vasopressins / blood

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Hazardous Substances Data Bank. VASOPRESSIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15513517.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Pyridines; 11000-17-2 / Vasopressins; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Wycliffe ND, Grover RS, Kim PD, Simental A Jr: Hypopharyngeal cancer. Top Magn Reson Imaging; 2007 Aug;18(4):243-58
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypopharyngeal cancer.
  • Hypopharyngeal cancers are usually squamous cell carcinomas (SCCs) that has the worst prognosis among the head and neck cancers.
  • Overall, 5-year survival rate remains poor despite recent improvements in diagnostic imaging, radiation and chemotherapy, and improved surgical techniques.
  • Hypopharyngeal cancers tend to present with advanced primary disease, and nodal metastasis is highly likely.
  • Distant metastasis at presentation is more common in hypopharyngeal cancers than in other head and neck cancers.
  • Poor survival rate is partly due to emergence of second primary cancers but also to development of distant metastasis.
  • Contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) remain the mainstay of initial radiological evaluation of hypopharyngeal cancer.
  • Imaging usually results in upstaging of the tumor at presentation.
  • Meticulous evaluation of the extent of the primary tumor with attention to spread to the subsites of the hypopharynx, larynx, and cartilage invasion are necessary for accurate staging.
  • After surgery and radiation therapy, it is difficult with CT and MR to differentiate residual and recurrent tumor from edema and scarring.
  • Fluorine 18-fluoro-deoxy-glucose -positron emission tomography (FDG-PET) has high sensitivity in detection of occult, residual, and recurrent tumors but has low specificity.
  • [MeSH-major] Hypopharyngeal Neoplasms / diagnosis. Hypopharyngeal Neoplasms / radiography. Hypopharynx / pathology. Magnetic Resonance Imaging. Tomography, X-Ray Computed
  • [MeSH-minor] Humans. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17893590.001).
  • [ISSN] 0899-3459
  • [Journal-full-title] Topics in magnetic resonance imaging : TMRI
  • [ISO-abbreviation] Top Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 138
  •  go-up   go-down


10. Kawecki A, Jarzabski A, Szutkowski Z, Kiprian D, Jagielska B: [Concomitant radiochemotherapy for locally advanced oro- and hypopharyngeal cancer: tolerance and early results]. Otolaryngol Pol; 2000;54 Suppl 31:27-30
Genetic Alliance. consumer health - Hypopharyngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concomitant radiochemotherapy for locally advanced oro- and hypopharyngeal cancer: tolerance and early results].
  • Combination of radio- and chemotherapy is one of the methods which may improve results of treatment in patients with locally advanced head and neck cancer.
  • Currently, the most promising sequence of radio- and chemotherapy is concomitant.
  • In Head and Neck Cancer Department of Cancer Center in Warsaw since 1995 is continued study estimated tolerance and effectiveness of the concomitant radiochemotherapy for patients with locally advanced oro- and hypopharyngeal cancer.
  • Chemotherapy consist of cisplatinum and 5-fluorouracil in continuous infusion during first week of irradiation followed by 24-hours infusion of 5-fluorouracil one weekly until radiotherapy is finished.
  • Radiotherapy is used with conventional fractionation 2 Gy per fraction, 5 fractions weekly to total dose 66 Gy.
  • Between October 1995 and September 1998 fifty seven patients with oropharyngeal cancer were entered to study.
  • Tolerance of treatment was acceptable.
  • Complete regression of the tumor was obtained in 41/57 patients (72%).
  • In 12 patients with hypopharyngeal cancer tolerance of treatment and early results were poor, so the study was stopped in this group.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiation Dosage. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10974836.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] POLAND
  •  go-up   go-down


11. Hirano S, Tateya I, Kitamura M, Kada S, Ishikawa S, Kanda T, Tanaka S, Ito J: Ten years single institutional experience of treatment for advanced hypopharyngeal cancer in Kyoto University. Acta Otolaryngol Suppl; 2010 Nov;(563):56-61
Genetic Alliance. consumer health - TEN.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ten years single institutional experience of treatment for advanced hypopharyngeal cancer in Kyoto University.
  • CONCLUSION: Treatment of advanced hypopharyngeal cancer has become more conservative and more multidisciplinary, and the prognosis has been improved.
  • Induction chemotherapy has the potential to extend organ preservation therapy even in cases with locally advanced primary lesion.
  • It is also important to develop a strategy to reduce distant metastasis and to keep track of second primary cancers.
  • OBJECTIVES: To update the therapeutic outcome of advanced hypopharyngeal cancer.
  • METHODS: A total of 72 cases with stage III/IV hypopharyngeal cancer were treated at Kyoto University Hospital during 2000-2008.
  • Radiotherapy (RT) with or without concurrent chemotherapy was applied in 16 cases.
  • Induction chemotherapy (ICT) has been applied for 14 cases since 2006 to achieve organ preservation and reduction of distant metastasis.
  • Therapeutic outcomes were chart reviewed.
  • In the end, 17 cases died of the primary disease, while 10 cases died of other causes, mainly second primary cancers.
  • [MeSH-major] Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Combined Modality Therapy. Female. Hospitals, University. Humans. Japan. Male. Middle Aged. Neoplasm Staging. Pharyngectomy. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20879820.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Rudat V, Pfreundner L, Hoppe F, Dietz A: Approaches to preserve larynx function in locally advanced laryngeal and hypopharyngeal cancer. Onkologie; 2004 Aug;27(4):368-75
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Approaches to preserve larynx function in locally advanced laryngeal and hypopharyngeal cancer.
  • Randomized controlled studies have shown that preservation of the larynx function in patients with advanced resectable laryngeal and hypopharyngeal cancer is possible without compromising survival compared to total laryngectomy (TL).
  • Options for preserving the larynx include function-sparing surgery, radiotherapy alone, induction chemotherapy followed by radiotherapy of responders, and concomitant radiochemotherapy.
  • The current data suggest that induction chemotherapy followed by radiotherapy of responders is an acceptable alternative to TL for patients desiring larynx preservation.
  • Concomitant radiochemotherapy (platinum/5-FU) leads to superior local control and larynx preservation rates compared to induction chemotherapy followed by radiation.
  • The optimal treatment sequence for newer cytotoxic agents is, however, unclear.
  • Predictive tests to successfully stratify patients for the optimal treatment option and more effective systemic therapy are needed to improve therapeutic possibilities and survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hypopharyngeal Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / surgery. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Laryngectomy. Neoadjuvant Therapy. Radiation-Sensitizing Agents / therapeutic use
  • [MeSH-minor] Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Neoplasm Staging. Platinum Compounds / administration & dosage. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Genetic Alliance. consumer health - Laryngeal cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15347892.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Platinum Compounds; 0 / Radiation-Sensitizing Agents; U3P01618RT / Fluorouracil
  • [Number-of-references] 78
  •  go-up   go-down


13. Miyahara H, Nario K, Matsushiro N, Sasai H, Kajikawa H: [Four cases of hypopharyngeal cancer treated with docetaxel, cisplatin, and 5-FU followed by radiotherapy and/or neck dissection]. Gan To Kagaku Ryoho; 2004 May;31(5):739-42
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Four cases of hypopharyngeal cancer treated with docetaxel, cisplatin, and 5-FU followed by radiotherapy and/or neck dissection].
  • We treated 4 patients with hypopharyngeal cancer, each of whom had a complete response after 2 cycles of chemotherapy with docetaxel, cisplatin, and 5-FU followed by radiation and/or neck dissection.
  • Twenty-one months to 2 years after this therapy, 3 patients had no recurrence and no metastasis with their laryngeal framework and function preserved.
  • Chemotherapy including docetaxel, cisplatin, and 5-FU is a useful treatment for early head and neck cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Drug Administration Schedule. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Leukopenia / chemically induced. Male. Middle Aged. Neck Dissection. Neoadjuvant Therapy. Prognosis. Radiotherapy Dosage. Taxoids / administration & dosage. Taxoids / adverse effects

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15170983.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Hasegawa Y, Hanai N, Terada A, Ozawa T, Goto M: Orotate phosphoribosyl transferase and XPA expressions as predictive biomarkers for combined chemotherapy with 5-fluorouracil and cisplatin in oro- and hypopharyngeal cancers. J Clin Oncol; 2009 May 20;27(15_suppl):6084

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orotate phosphoribosyl transferase and XPA expressions as predictive biomarkers for combined chemotherapy with 5-fluorouracil and cisplatin in oro- and hypopharyngeal cancers.
  • : 6084 Background: The main purpose of the present study was to find predictive biomarkers that can be routinely used for the response to chemotherapy in head and neck squamous cell carcinomas.
  • METHODS: Sixty-four tumor specimens from patients undergoing radical treatment for squamous cell carcinomas of the oro- and hypopharynx in stage II, III, or IV, were included in the present study.
  • There were 30 primary tumors sites in the oropharynx and 34 in the hypopharynx, respectively.
  • All patients were administered induction chemotherapy (FP) with a combination of 5-FU (800 (600) mg/m<sup>2</sup> d1-5 (6)) and cisplatin (80 mg/m<sup>2</sup> d6 (7)) before definitive therapy.
  • This chemotherapy was used in order to select patients for organ preservation based on the response and decrease in late salvage surgery rate.
  • Treatment was repeated every 3 to 4 weeks.
  • Using biopsy specimens, we analyzed their gene expression profiles with the following 25 markers, which we thought were likely predictors of the response to anti-cancer agents: TS, DPD, OPRT, TP, COX2, MDR1, MRP1, VEGF, EGFR, HER2, PIK3CA, PTEN, p53, Rb1, Bcl2, BclX, BAX, GSTπ, ERCC1, XPA, E2F1, ENT1, Rev3, β-tubulin, and Survivin.
  • These mRNA expressions were quantified by real-time reverse transcription polymerase chain reaction (real-time RT-PCR) assay.
  • RESULTS: Univariately, response for chemotherapy was significantly correlated with T factor (p = 0.015), and the mRNA expression level of XPA (p = 0.018) and OPRT (p = 0.047).
  • Meanwhile, using a multivariate logistic regression analysis with these factors (clinical markers, OPRT and XPA), T factor (p = 0.048) and the expression of XPA (p = 0.035) were demonstrated to be independent predictors for chemotherapy.
  • CONCLUSIONS: XPA (Xeroderma Pigmentosum A) and OPRT (Orotate phosphoribosyl transferase) may be possible reliable predictive biomarkers for FP therapy, and might help the decision-making strategy for individual patients with head and neck cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961950.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Deshpande HA, Gettinger S, Rowen E, Abu-Khalaf MM, Clarke J, Burns AJ, Kelly WK: A phase I study investigating the combination of orally bioavailable platinum and nanoparticle albumin-bound paclitaxel in advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e13501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e13501 Background: The combination of a taxane and a platinum agent is considered a standard chemotherapy regimen for many solid tumors.
  • Adverse effects often limit the administration of these drugs.
  • The nanoparticle albumin-bound paclitaxel (A) has shown greater efficacy and less toxicity than Cremophor-based paclitaxel as a single agent in the treatment of breast cancer.
  • Blood samples for PK studies were drawn with the day -14 and Day 1 treatments.
  • RESULTS: To date 15 pts (2 renal, 3 prostate, 2 bladder, 1 hypopharyngeal, 1 mesothelioma, 1 colorectal, 1 melanoma and 2 leiomyosarcomas) with a median age 51 (range 37 - 78 yrs) have been treated in 3 cohorts.
  • 1 patient (testicular cancer) intended for cohort 1 was a screen failure.
  • To date 6 patients had progressive disease, 4 had stable disease (3.8 months), 3 patients (2 with prostate cancer and 1 with hypopharyngeal cancer) had a partial response.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961256.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Karasawa K, Umezawa T, Hanyu N, Kawamura H, Kiguchi Y, Mitsuhashi T, Niibe Y: Hyperfractionated radiation therapy for the treatment of squamous cell carcinoma of the head and neck. J Clin Oncol; 2004 Jul 15;22(14_suppl):5554

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperfractionated radiation therapy for the treatment of squamous cell carcinoma of the head and neck.
  • : 5554 Background: Altered fractionation radiation therapy has been thought to improve the local control and survival of the patients with head and neck cancer.
  • Since 1996, we have been conducting a clinical trial of hyperfractionated radiation therapy (HFRT) for the treatment of squamous cell carcinoma of the head and neck (SCCHN).
  • Primary site: Larynx 34 cases, hypopharynx 27 cases, oropharynx 17 cases, oral cavity 5 cases, nasopharynx 4 cases, and maxillary sinus 2 cases.
  • Chemotherapy was combined in 22 cases.
  • As for hypopharynx, OS and LC of overall, stage I-II, and stage III-IV were, 49.9%, 65.3%, 53.6%, 100%, and 48.2%, 42.9%, respectively.
  • Disease-specific survival of stage I-II hypopharyngeal cancer was 100%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013972.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Okamoto M, Takahashi H, Yao K, Inagi K, Nakayama M, Nagai H: Clinical impact of using chemoradiotherapy as a primary treatment for hypopharyngeal cancer. Acta Otolaryngol Suppl; 2002;(547):11-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical impact of using chemoradiotherapy as a primary treatment for hypopharyngeal cancer.
  • Eighty-eight patients with hypopharyngeal cancer who received chemoradiotherapy as the primary treatment between 1979 and 1997 were investigated.
  • Forty-six patients who received surgery as the primary treatment were analyzed as a control group.
  • There were no statistically significant differences regarding TN classification, tumor stage, tumor site, age or sex between the radiation and surgery groups.
  • Among patients with residual tumor, a salvage operation was employed in 31 cases, 13 patients refused to receive surgery and 8 were inoperable.
  • Based on the 5-year survival, primary CR, salvage and laryngeal preservation rates, we conclude that chemoradiotherapy is a good primary treatment for hypopharyngeal cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cisplatin / therapeutic use. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Radiation-Sensitizing Agents / therapeutic use. Tegafur / therapeutic use. Uracil / therapeutic use
  • [MeSH-minor] Chemotherapy, Adjuvant. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Outcome Assessment (Health Care). Pharynx / drug effects. Pharynx / radiation effects. Radiotherapy Dosage. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12212584.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Radiation-Sensitizing Agents; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Chen SW, Yang SN, Liang JA, Lin FJ, Tsai MH: Prognostic impact of tumor volume in patients with stage III-IVA hypopharyngeal cancer without bulky lymph nodes treated with definitive concurrent chemoradiotherapy. Head Neck; 2009 Jun;31(6):709-16
Genetic Alliance. consumer health - Hypopharyngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of tumor volume in patients with stage III-IVA hypopharyngeal cancer without bulky lymph nodes treated with definitive concurrent chemoradiotherapy.
  • BACKGROUND: To investigate the prognostic value of volumetric analysis in patients with stage III-IVA hypopharyngeal cancer treated with concurrent chemoradiotherapy (CCRT).
  • METHODS: Seventy-six stage III-IVA hypopharyngeal cancer patients without bulky lymph nodes were enrolled for a volumetric analysis.
  • The pyriform sinus was the principal site of involvement in the 63 cases.
  • Tumor volume measurement was derived using separate calculations for the primary tumor volume (pGTV) and the nodal tumor volume (nGTV).
  • Furthermore, the 3-year primary tumor relapse-free survival (PRFS) was 72% for those with a pGTV <30 mL and 23% when the pGTV were >or=30 mL (p = .0001).
  • CONCLUSION: A patient's pGTV is a strong outcome predictor for hypopharyngeal cancer treatment using CCRT.
  • Therefore, a selected group of patients, mainly those with tumor volumes <30 mL should be considered for laryngeal preservation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / therapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Cohort Studies. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Probability. Prognosis. Proportional Hazards Models. Radiotherapy Dosage. Retrospective Studies. Risk Assessment. Survival Analysis. Taiwan. Treatment Outcome. Tumor Burden / drug effects. Tumor Burden / radiation effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley Periodicals, Inc.
  • (PMID = 19260114.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Mochiki M, Sugasawa M, Nibu K, Asai M, Nakao K, Asakage T: Prognostic factors for hypopharyngeal cancer: a univariate and multivariate study of 142 cases. Acta Otolaryngol Suppl; 2007 Dec;(559):136-44
Genetic Alliance. consumer health - Hypopharyngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for hypopharyngeal cancer: a univariate and multivariate study of 142 cases.
  • Effective adjuvant chemotherapy should be developed for patients with advanced primary disease (T>2) as well as for patients with advanced nodal status (N>0 or PLN>2).
  • OBJECTIVES: The aim of this study was to identify prognostic factors for hypopharyngeal cancer.
  • Surgical resection was administered as primary treatment to 116 of the patients (82%), while 26 patients (18%) underwent primary radiotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Hypopharyngeal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Laryngectomy. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Pharyngectomy. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18340585.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


20. Dietz A, Rudat V, Dreyhaupt J, Pritsch M, Hoppe F, Hagen R, Pfreundner L, Schröder U, Eckel H, Hess M, Schröder M, Schneider P, Jens B, Zenner HP, Werner JA, Engenhardt-Cabillic R, Vanselow B, Plinkert P, Niewald M, Kuhnt T, Budach W, Flentje M: Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial). Eur Arch Otorhinolaryngol; 2009 Aug;266(8):1291-300
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial).
  • A prospective multicenter phase-II trial (12 centers) was performed by the German larynx organ preservation group (DeLOS) to evaluate the effect of induction chemotherapy (ICHT) with paclitaxel/cisplatin (TP), followed by accelerated-hyperfractionated (concomitant boost) radiotherapy (RT) in responders.
  • The trial was focused on larynx preservation, tumor control, survival, salvage surgery and late toxicity in patients with advanced larynx/hypopharynx carcinoma eligible for total laryngectomy (LE).
  • Seventy-one patients (40 larynx, 87.5% St. III, IV; 31 hypopharynx, 93.4% St. III, IV) were enrolled into the study and treated with ICHT (200 mg/m(2) paclitaxel, 100 mg/m(2) cisplatin; day 1, 22) according to the DeLOS protocol.
  • Patients with complete or partial tumor response proceeded to RT (69.9 Gy in 5.5 weeks).
  • Non-responders received a LE followed by postoperative RT (56-70 Gy in 5.5-7 weeks).
  • The response rate to ICHT for larynx cancer was 69.6% (7.1% complete, 62.5% partial response) and for hypopharyngeal cancer was 84.3% (6.9% complete, 77.4% partial response).
  • Both parameters did not show different outcomes after distinguishing larynx from hypopharynx.
  • LE was indicated in 15 non-responders after ICHT.
  • Five of the 15 non-responders refused the laryngectomy.
  • [MeSH-major] Cisplatin / administration & dosage. Hypopharyngeal Neoplasms / drug therapy. Laryngeal Neoplasms / drug therapy. Larynx / radiation effects. Paclitaxel / administration & dosage
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / administration & dosage. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Genetic Alliance. consumer health - Laryngeal cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] HNO. 1998 Aug;46(8):731-8 [9773329.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1198-204 [18086960.001]
  • [Cites] Ann Otol Rhinol Laryngol Suppl. 1998 May;172:1-27 [9597955.001]
  • [Cites] Laryngoscope. 2008 Apr;118(4):759-60 [18300709.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2624-8 [16763275.001]
  • [Cites] Radiother Oncol. 2003 Aug;68(2):163-70 [12972311.001]
  • [Cites] Laryngoscope. 2006 Sep;116(9 Pt 2 Suppl 111):1-13 [16946667.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):593-8 [16380415.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2636-43 [16763277.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1041-2 [7713774.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):93-8 [12504040.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):19-22 [14657230.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1695-704 [17960012.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1705-15 [17960013.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Acta Oncol. 1999;38(8):1025-30 [10665757.001]
  • [Cites] HNO. 2002 Feb;50(2):146-54 [12080625.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):735-6; author reply 736 [17308284.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1161-71 [11483325.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2603-5 [16763271.001]
  • [Cites] Head Neck. 1997 Oct;19(7):567-75 [9323144.001]
  • (PMID = 18972123.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Saarilahti K, Kajanti M, Atula T, Mäkitie A, Aaltonen LM, Kouri M, Mäntylä M: Biweekly escalated, accelerated hyperfractionated radiotherapy with concomitant single-dose mitomycin C results in a high rate of local control in advanced laryngeal and hypopharyngeal cancer. Am J Clin Oncol; 2004 Dec;27(6):589-04
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biweekly escalated, accelerated hyperfractionated radiotherapy with concomitant single-dose mitomycin C results in a high rate of local control in advanced laryngeal and hypopharyngeal cancer.
  • The purpose of this study is to evaluate the efficacy of a dose-escalated, accelerated, and hyperfractionated radiotherapy schedule with a concomitant single dose of mitomycin C in the treatment of patients with advanced laryngeal or hypopharyngeal cancer.
  • Twenty-one previously untreated patients with advanced squamous cell carcinoma (stage III, n = 6; stage IV, n = 15) were treated with a biweekly dose-escalated, accelerated, and hyperfractionated schedule up to a total dose of 74.4 Gy in 54 fractions over 5 weeks.
  • The median follow-up after treatment of surviving patients is 48 months (range, 28 to 61 months).
  • All patients showed complete tumor control at the primary site when evaluated 2 months after chemoirradiation by laryngomicroscopy or hypopharyngoscopy and radiologic imaging (CT, MRI).
  • Two laryngectomies were carried out after given therapy: 1 for residual cancer and 1 for suspected residual cancer.
  • After a median follow-up of 43 months (range, 28 to 61 months), a local control rate of 70% and disease-free survival (DFS) rate of 60% were achieved in the laryngeal cancer patients; in patients with hypopharyngeal cancer, the corresponding figures were 64% (82% after salvage surgery) and 36%.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Mitomycin / therapeutic use
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose Fractionation. Female. Humans. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15577437.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


22. Tsou YA, Hua JH, Lin MH, Tsai MH: Analysis of prognostic factors of chemoradiation therapy for advanced hypopharyngeal cancer--does tumor volume correlate with central necrosis and tumor pathology? ORL J Otorhinolaryngol Relat Spec; 2006;68(4):206-12
Genetic Alliance. consumer health - Hypopharyngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of prognostic factors of chemoradiation therapy for advanced hypopharyngeal cancer--does tumor volume correlate with central necrosis and tumor pathology?
  • OBJECTIVES: Not all patients with hypopharyngeal cancer who undergo concurrent chemoradiation therapy have a good prognosis.
  • We hope to find the significant prognostic factors that could help us in patient selection for concurrent chemoradiation therapy.
  • STUDY DESIGN: We used a retrospective analysis on several prognostic factors which may affect the treatment outcome and prognosis.
  • METHODS: We studied 51 patients with stage III-IV hypopharyngeal cancer who underwent chemoradiation therapy as the first treatment method.
  • Possible significant prognostic factors (i.e. tumor volume, central necrosis, pathology, age) were collected to determine whether they correlate with local disease control and survival.
  • RESULTS: Primary tumor volume correlated with local disease control and survival.
  • The greatest risk for local failure was found among patients with primary tumor volumes >19.0 ml (p = 0.001).
  • The survival rate among patients with primary tumor volumes >19.0 ml was only 39.3% compared with 78.3% for patients with volumes <19.0 ml (p = 0.036).
  • A proportional hazard model indicated that significant parameters associated with overall survival were primary tumor volume (p = 0.036) and central necrosis (p = 0.008).
  • According to the cancer cell differentiation, the hazard risk in the well-differentiated group was 5.62 folds higher than in the poorly differentiated group (p = 0.05).
  • Patients with an initial complete response had a primary tumor volume <19 ml (p = 0.001, 0.016), poorly differentiated pathology (p = 0.001, 0.016), and no central necrosis (p = 0.001, 0.016).
  • CONCLUSION: Tumor volume is the most important prognostic factor of treatment outcome for patients with hypopharyngeal cancer and should always be taken into consideration in treatment planning.
  • Other possible prognostic factors which affect the initial complete response rate and survival rate including central necrosis, pathology, nodal number and nodal volume, T stage above III, and cervical lymphadenopathy beyond level II have a relatively low correlation with treatment outcome.
  • In our study, there was a correlation between tumor volume and central necrosis, but no significant correlation between pathological differentiation and tumor volume, although both affect treatment outcome.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Kaplan-Meier Estimate. Logistic Models. Lymph Nodes / pathology. Male. Middle Aged. Necrosis. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Factors. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel.
  • (PMID = 16508339.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


23. Major MS, Bumpous JM, Flynn MB, Schill K: Quality of life after treatment for advanced laryngeal and hypopharyngeal cancer. Laryngoscope; 2001 Aug;111(8):1379-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life after treatment for advanced laryngeal and hypopharyngeal cancer.
  • OBJECTIVES: To compare health-related quality of life measures after treatment for advanced (stages III and IV) laryngeal and hypopharyngeal cancers.
  • METHODS: Our study included 54 patients identified from the Tumor Registry of the University of Louisville Brown Cancer Center who were diagnosed and treated between 1995 and 2000.
  • Demographics, tumor data, and treatment information were obtained from the Tumor Registry database.
  • RESULTS: Fifteen patients were treated with chemotherapy and radiation therapy (CRT).
  • Six patients underwent surgery with postoperative radiation therapy (SRT).
  • The remaining three patients were treated with radiation therapy but were not used in this analysis.
  • The average follow-up was 35 months after treatment.
  • The CRT and SRT groups were statistically similar regarding age, sex, duration of follow-up, tumor grade, and tumor stage.
  • CONCLUSIONS: These results indicate that only one of eight domains differs significantly between treatment groups when using the HSQ-12.
  • Two-year survival end-point analysis of global health assessment may represent a simplified and meaningful way to compare treatment modalities in patients with advanced-stage head and neck cancer.
  • [MeSH-major] Health Status Indicators. Hypopharyngeal Neoplasms / therapy. Laryngeal Neoplasms / therapy. Quality of Life
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11568572.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


24. Tai SK, Yang MH, Wang LW, Tsai TL, Chu PY, Wang YF, Huang JL, Chang SY: Chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer. Jpn J Clin Oncol; 2008 Aug;38(8):521-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer.
  • OBJECTIVE: Laryngeal preservation is a challenge for the treatment of advanced hypopharyngeal cancer.
  • The objective of this study is to evaluate the results of chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer at a single institute and the impact of treatment factors on prognosis.
  • METHODS: The study population consisted of 42 consecutive patients with resectable stage III-IV hypopharyngeal cancer.
  • Patients with T4b tumor, synchronous primary cancer or those treated palliatively were excluded.
  • Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) was performed in 32 (76.2%) patients, whereas primary CCRT was done in the other 10 (23.8%).
  • Patients were grouped according to the dose intensity of chemotherapy and total dose of radiotherapy (RT).
  • CONCLUSIONS: Achievement of optimum treatment dose remains challenging in chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer.
  • The criteria for selecting patients who will respond to and complete the treatment remain key issues for future investigation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Hypopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Larynx / pathology. Male. Methotrexate / administration & dosage. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome. X-Rays

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Genetic Alliance. consumer health - Laryngeal cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697758.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


25. Hirano S, Tateya I, Kitamura M, Kada S, Ishikawa S, Kanda T, Tanaka S, Ito J: Organ preservation surgery for advanced hypopharyngeal cancer. Acta Otolaryngol Suppl; 2010 Nov;(563):50-5
Genetic Alliance. consumer health - Hypopharyngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ preservation surgery for advanced hypopharyngeal cancer.
  • CONCLUSION: Organ preservation surgery with partial pharyngectomy preserving the larynx is feasible for the treatment of advanced hypopharyngeal cancer with comparable local control and preservation of function.
  • OBJECTIVES: To examine the feasibility and therapeutic effects of organ preservation surgery for advanced hypopharyngeal cancer.
  • METHODS: Fourteen patients with stage III/IV hypopharyngeal cancer were treated by partial pharyngectomy with or without partial laryngectomy to preserve the larynx.
  • Induction chemotherapy was administered for six cases including three with T3/4 tumors.
  • [MeSH-major] Hypopharyngeal Neoplasms / therapy. Pharyngectomy
  • [MeSH-minor] Aged. Cohort Studies. Combined Modality Therapy. Female. Humans. Laryngectomy. Male. Middle Aged. Neck Dissection. Neoplasm Staging. Retrospective Studies. Surgical Flaps. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20879819.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Pivot X, Magné N, Guardiola E, Poissonnet G, Dassonville O, Francoual M, Formento JL, Bensadoun RJ, Demard F, Schneider M, Milano G: Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer. Oral Oncol; 2005 Mar;41(3):320-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer.
  • The aim of this study was to analyse prognostic factors for disease free interval (DFI) and overall survival (OS) among patients with larynx and hypopharynx cancer requiring a total laryngectomy.
  • Three groups of patients were studied according to the type of treatment they received.
  • Fifty-eight patients had total laryngectomy, 71 patients had organ preservation treatment including induction chemotherapy followed by exclusive radiotherapy, 26 patients received induction chemotherapy followed by salvage total laryngectomy.
  • The studied potential prognostic factors were age, gender, performans status, primary tumor localization, T status, N status, tumor volume and tumoral EGFR level (fmol/mg protein).
  • The multivariate analysis showed that both N status and tumor volume were significant for DFI and OS.
  • EGFR level was significant only for patients treated by induction chemotherapy and exclusive radiotherapy (p = 0.05 and 0.05 for DFI and OS length, respectively).
  • Among this group, patients with tumor EGFR levels lower and higher than 100 fmol/mg protein had 53% versus 22% and 51% versus 18% 5-year of DFI and OS rates, respectively (Log rank test: p = 0.001 and 0.0001).
  • EGFR determination appears to be a powerful prognostic parameter for patients treated by induction chemotherapy followed by exclusive radiotherapy.
  • These results profile the use of EGFR targeting therapy for this category of patients.
  • [MeSH-major] Biomarkers, Tumor / analysis. Hypopharyngeal Neoplasms / chemistry. Laryngeal Neoplasms / chemistry. Receptor, Epidermal Growth Factor / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Humans. Laryngectomy. Male. Middle Aged. Multivariate Analysis. Retrospective Studies. Survival Rate

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15743695.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


27. Lee MS, Ho HC, Hsiao SH, Hwang JH, Lee CC, Hung SK: Treatment results and prognostic factors in locally advanced hypopharyngeal cancer. Acta Otolaryngol; 2008 Jan;128(1):103-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results and prognostic factors in locally advanced hypopharyngeal cancer.
  • CONCLUSIONS: We suggest that concurrent chemoradiation (CCRT) is an effective definitive treatment for patients with advanced hypopharyngeal carcinoma who are unfit for or refuse surgery.
  • A high dose of radiation (> 70 Gy) should be given to achieve acceptable local control rates and survival.
  • OBJECTIVES: The purpose of this retrospective study was to compare the treatment results of locally advanced hypopharyngeal carcinoma with two different protocols.
  • PATIENTS AND METHODS: From December 1995 to December 2004, 74 patients with locally advanced hypopharyngeal cancer were treated with CCRT or surgery plus postoperative radiotherapy (SRT).
  • Their treatment results were reviewed by retrospective analysis.
  • RESULTS: There was no significant difference in T and N status between the two treatment groups, nor were there significant differences in overall or disease-free survival or the incidence of distant metastasis (p >0.05).
  • Radiation doses >70 Gy yielded significantly better survival and local control than doses <70 Gy (p <0.05).
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Esophagectomy. Female. Fluorouracil / administration & dosage. Humans. Hypopharynx / pathology. Hypopharynx / surgery. Kaplan-Meier Estimate. Laryngectomy. Male. Middle Aged. Neoplasm Staging. Pharyngectomy. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17851955.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


28. Kawashima M, Hayashi R, Tahara M, Yamazaki M, Miyazaki M, Arahira S, Ogino T: Accelerated radiotherapy and larynx preservation in favorable-risk patients with T2 or worse hypopharyngeal cancer. Jpn J Clin Oncol; 2007 May;37(5):345-52
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accelerated radiotherapy and larynx preservation in favorable-risk patients with T2 or worse hypopharyngeal cancer.
  • OBJECTIVE: To evaluate the advantage of accelerated fractionation radiotherapy for patients with hypopharyngeal cancer requiring total laryngectomy.
  • METHODS: Seventy patients with previously untreated, technically resectable hypopharyngeal cancer who received larynx-preserving treatment with radiotherapy between April 1992 and June 2004 were analyzed.
  • A total RT dose of > or = 60 Gy/6 weeks was determined depending on the tumor clearance during treatment before December 1998, and fixed to 70 Gy in all patients thereafter.
  • Accelerated fractionation (70 Gy/<49 days) was completed in 35 patients during the latter period.
  • Concomitant platinum-based chemotherapy was used in 41 patients after May 1998.
  • Patients who had received 70 Gy/<49 days achieved a better local control rate than those who had received other, more conservative total dose/overall treatment time with statistical significance (91% versus 50% at 2 years, P < 0.001).
  • Multivariate analysis involving 70 Gy/<49 days of radiotherapy, T-classification (T2 versus T3/4), and use of chemotherapy revealed that administering 70 Gy/<7 weeks was the only independent prognostic factor (P = 0.007) for better local control.
  • CONCLUSIONS: Our experience in radiotherapy for hypopharyngeal cancer mirrored the results of previously conducted large randomized trials for various head and neck cancers.
  • Encouraging local control in this study warrants prospective study to test the long-term oncological and functional outcome of larynx-preserving treatment in patients with advanced but resectable volume of this disease.
  • [MeSH-major] Hypopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Follow-Up Studies. Humans. Larynx. Neoplasm Recurrence, Local. Radiotherapy Dosage. Salvage Therapy. Tegafur / therapeutic use. Treatment Outcome. Uracil / therapeutic use

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17584824.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q20Q21Q62J / Cisplatin; FP protocol
  •  go-up   go-down


29. Kohno N, Kitahara S: [Chemotherapy for head and neck cancer]. Gan To Kagaku Ryoho; 2000 Feb;27(2):177-82
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy for head and neck cancer].
  • Chemotherapy for head and neck cancer was initially used as a palliative treatment in advanced and/or recurrent disease.
  • It was also observed that complete responders had a significantly longer survival period than non-responders.
  • In a large number of randomized trials, organ function preservation studies have shown the possibility of laryngeal preservation for T2 and T3 laryngeal and hypopharyngeal cancer.
  • A survival benefit has been shown clearly in advanced nasopharyngeal cancer.
  • Another survival prolongation has been demonstrated in cases of locally unresectable cancer in the oral cavity, pharynx, nose and paranasal sinus.
  • Thus, we conclude that neoadjuvant chemotherapy can be effective in cases of locally unresectable cancer in the oral cavity, pharynx, and nose and paranasal sinus.
  • In advanced N stage nasopharyngeal cancer, neoadjuvant chemotherapy plus adjuvant chemotherapy may be indicated.
  • Advanced T stage nasopharyngeal cancer is a good candidate for concurrent chemoradiotherapy.
  • For the aim of laryngeal preservation, neoadjuvant and/or concurrent chemoradiotherapy can be indicated for T2 and T3 laryngeal and hypopharyngeal cancer.
  • [MeSH-major] Evidence-Based Medicine. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Palliative Care. Randomized Controlled Trials as Topic. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10700887.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Number-of-references] 21
  •  go-up   go-down


30. Kohno N, Kitahara S: [Role of Chemotherapy in head and neck cancer]. Gan To Kagaku Ryoho; 2001 Apr;28(4):448-53
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of Chemotherapy in head and neck cancer].
  • For head and neck cancer, a recent meta-analysis of published randomized trial results showed that concurrent chemoradiotherapy, adjuvant chemotherapy and neoadjuvant chemotherapy may increase absolute survival by 12.1%, 6.5%, and 3.7%, respectively.
  • Initial response rates to first line chemotherapy are high, but this responsiveness does not appear to translate into a survival benefit.
  • Thus, chemotherapy can be indicated as the standard therapy for a very limited range of advanced head and neck cancers.
  • With the aim of prolonging survival, N stage advanced nasopharyngeal cancer is a good candidate for neoadjuvant chemotherapy.
  • Among a large number of randomized trials of neoadjuvant chemotherapy, organ function preservation studies showed the possibility of laryngeal preservation for locally resectable T2 and T3 laryngeal and hypopharyngeal cancer.
  • Concurrent chemoradiotherapy may be indicated for advanced T stage head and neck cancers, especially those with locally unresectable lesions.
  • For N stage advanced pharyngeal cancer patients, adjuvant chemotherapy with applied after the standard therapy has a role in the treatment.
  • With palliative treatment in advanced and/or recurrent disease, there is less benefit from chemotherapy and indications for chemotherapy should be selected for individual patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Cisplatin / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Drug. Fluorouracil / administration & dosage. Humans. Palliative Care. Quality of Life. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11329777.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 11
  •  go-up   go-down


31. Huang WY, Jen YM, Chen CM, Su YF, Lin CS, Lin YS, Chang YN, Chao HL, Lin KT, Chang LP: Intensity modulated radiotherapy with concurrent chemotherapy for larynx preservation of advanced resectable hypopharyngeal cancer. Radiat Oncol; 2010;5:37
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity modulated radiotherapy with concurrent chemotherapy for larynx preservation of advanced resectable hypopharyngeal cancer.
  • BACKGROUND: To analyze the rate of larynx preservation in patients of locally advanced hypopharyngeal cancer treated with intensity modulated radiotherapy (IMRT) plus concurrent chemotherapy, and compare the results with patients treated with primary surgery.
  • The 5-year overall survival rate was 33% and 44% for primary surgery and definitive CCRT, respectively (p = 0.788).
  • The rates of treatment-related mucositis (> or = grade 2) and pharyngitis (> or = grade 3) were higher in the CCRT group.
  • For multivariate analysis, treatment response and cricoid cartilage invasion strongly correlated with survival.
  • CONCLUSIONS: IMRT plus concurrent chemotherapy may preserve the larynx without compromising survival.
  • Further studies on new effective therapeutic agents are essential.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Radiation. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 1996 Sep-Oct;18(5):405-11 [8864731.001]
  • [Cites] Radiother Oncol. 2009 Jul;92(1):4-14 [19446902.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1419-26 [16154712.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):363-73 [15925451.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Strahlenther Onkol. 2006 Jun;182(6):331-5 [16703288.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):876-83 [10679658.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2618-23 [16763274.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):966-74 [17145527.001]
  • [Cites] Oncologist. 2007 May;12(5):555-64 [17522243.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):459-68 [17493769.001]
  • [Cites] Lancet Oncol. 2008 Apr;9(4):367-75 [18374290.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):424-32 [18755554.001]
  • [Cites] Int J Cancer. 2000 Apr 20;90(2):92-103 [10814959.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2001 Feb;26(1):59-61 [11298170.001]
  • [Cites] Head Neck. 2001 Sep;23(9):713-7 [11505479.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):12-22 [12007936.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):92-8 [12506176.001]
  • [Cites] World J Surg. 2003 Jul;27(7):832-7 [14509515.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1991 Oct;16(5):466-9 [1742894.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1873-8 [8410112.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):838-47 [8622032.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] Acta Oncol. 2009;48(3):431-9 [18781445.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 3;90(11):824-32 [9625170.001]
  • (PMID = 20470428.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2890614
  •  go-up   go-down


32. Rubio Suárez A, Teigeiro Núñez V, Gallo Terán J, Señaris González B, Mesuro Domínguez N: [Induction chemotherapy using vinorelbine, cisplatin, and UFT in advanced pharyngeo-laryngeal carcinomas: results of a phase II study]. Acta Otorrinolaringol Esp; 2003 Dec;54(10):697-703
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction chemotherapy using vinorelbine, cisplatin, and UFT in advanced pharyngeo-laryngeal carcinomas: results of a phase II study].
  • [Transliterated title] Quimioterapia de inducción con vinorelbine, cisplatino y UFT en carcinomas avanzados faringo-laríngeos: resultados de un estudio fase II.
  • OBJECTIVE: To evaluate the results of an induction chemotherapy protocol with Vinorelbine, UFT and Cisplatin (UFTVP).
  • METHODS: 93 patients with laryngo-pharyngeal squamous cell carcinoma in stage III or IV were prospectively entered into a protocol to receive four cycles of UFTVP.
  • Responders followed definitive radiation therapy.
  • RESULTS: Following chemotherapy nodal response (complete in 28% and partial in 33%) was less than that the primary site (complete in 60% and partial in 30%), p = 0.002.
  • Successful larynx preservation was achieved in 50% of patients with laryngeal cancer and in 29% of patients with hypopharyngeal cancer.
  • CONCLUSIONS: UFTVP is an active regime of chemotherapy in advanced squamous cell carcinoma of the pharynx and larynx.
  • Results differ according to the localization, having significantly better rates of survival and organ preservation in the laryngeal cancers that in those of the pharynx.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Laryngeal Neoplasms / drug therapy. Pharyngeal Neoplasms / drug therapy. Tegafur / therapeutic use. Uracil / therapeutic use. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Alcohol Drinking / adverse effects. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / mortality. Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / surgery. Laryngectomy. Life Tables. Lymphatic Metastasis. Male. Middle Aged. Neoadjuvant Therapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / mortality. Oropharyngeal Neoplasms / pathology. Oropharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / surgery. Prospective Studies. Remission Induction. Risk Factors. Smoking / adverse effects. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15164709.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine; 1-UFT protocol
  •  go-up   go-down


33. Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, Guerrif S, Alfonsi M, Calais G: Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst; 2009 Apr 1;101(7):498-506
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.
  • BACKGROUND: Chemotherapy with cisplatin (P) and 5-fluorouracil (F) followed by radiotherapy in patients who respond to chemotherapy is an alternative to total laryngectomy for patients with locally advanced larynx and hypopharynx cancer.
  • METHODS: Patients who had larynx and hypopharynx cancer that required total laryngectomy were randomly assigned to receive three cycles of TPF or PF.
  • Patients who responded to chemotherapy received radiotherapy with or without additional chemotherapy.
  • Patients who did not respond to chemotherapy underwent total laryngectomy followed by radiotherapy with or without additional chemotherapy.
  • RESULTS: Baseline patient and tumor characteristics were well balanced between the TPF (n = 110) and PF (n = 103) groups.
  • CONCLUSIONS: In patients with advanced larynx and hypopharynx carcinomas, TPF induction chemotherapy was superior to the PF regimen in terms of overall response rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / surgery. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / surgery. Laryngectomy / methods. Neoadjuvant Therapy / methods
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / adverse effects. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Karnofsky Performance Status. Male. Middle Aged. Radiotherapy, Adjuvant / adverse effects. Remission Induction. Taxoids / administration & dosage. Treatment Outcome. Young Adult

  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2009 Aug 19;101(16):1157-8; author reply 1158 [19567423.001]
  • (PMID = 19318632.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


34. Sarini J, Bocciolini C, Fournier C, Penel N, Kara A, Van JT, Lefebvre JL: [Induction chemotherapy and larynx preservation: is such practice useful?]. Bull Cancer; 2002 Apr;89(4):411-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction chemotherapy and larynx preservation: is such practice useful?].
  • [Transliterated title] Chimiothérapie d'induction et préservation laryngée qu'en est-il en pratique?
  • BACKGROUND: Surgery followed by irradiation is considered to be the standard treatment but require frequently a total laryngectomy.
  • Chemotherapy followed by irradiation is available in larynx and hypopharynx squamous cell carcinoma (SCC) treatment.
  • Are results obtained in daily induction chemotherapy usefulness identical to results obtained in larynx preservation studies?
  • PATIENTS AND METHOD: We conducted a retrospective study on patients treated at centre Oscar-Lambret, Lille, from 1986 to 1995, by chemotherapy followed by definitive radiotherapy or by surgery and radiotherapy for laryngeal or hypopharyngeal cancer treatment.
  • All patients were naive of previous head and neck SCC and a surgical treatment, requiring total laryngectomy, should be proposed with curative intent.
  • Induction chemotherapy associated cisplatin (100 mg/m2) on day 1 and 5-fluorouracil (5FU)(1,000 mg/m2) on days 1-4 or 1-5.
  • If case of non-responder, patients underwent surgical treatment followed by irradiation.
  • We found a higher frequency of laryngeal tumour in group 2 (31 vs 17; p =.03).
  • For chemotherapy-related toxic reactions, the exclusive statistical difference observed was haematological toxicity grade III and IV after the second cycle (0 pt in group 1 vs 8 pts in group 2; p =.02).
  • After initial treatment, complete response was achieved without statistical difference between the groups (88.2% vs 78%; p =.27).
  • A surgical procedure was performed in 46 cases without difference according to the reference group and functional larynx preservation was 55.8% (29/52) in group 1 and 53.6% (30/56) in group 2.
  • Cancer was the first cause of death in both groups.
  • Some parameters influenced the overall survival like T (p =.04), response to chemotherapy (p=.006), extra capsular spread (p = 0.03) and response after completion treatment.
  • CONCLUSION: Induction chemotherapy is available for larynx preservation but cannot be considered as a standard treatment.
  • Nevertheless, results should be reproduced in daily practice with experimented teams as found with non included patient's results.
  • Recent publication, on increase postoperative infection after chemotherapy, should be evaluated in clinical trial.
  • Larynx preservation remains an interesting point of view for patients but stay an optional procedure and not a reference.
  • [MeSH-major] Carcinoma, Squamous Cell. Hypopharyngeal Neoplasms. Laryngeal Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Laryngectomy / methods. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Survival Analysis

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12016041.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


35. Terayama N, Sanada J, Matsui O, Kobayashi S, Kawashima H, Yamashiro M, Takanaka T, Kumano T, Yoshizaki T, Furukawa M: Feeding artery of laryngeal and hypopharyngeal cancers: role of the superior thyroid artery in superselective intraarterial chemotherapy. Cardiovasc Intervent Radiol; 2006 Jul-Aug;29(4):536-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feeding artery of laryngeal and hypopharyngeal cancers: role of the superior thyroid artery in superselective intraarterial chemotherapy.
  • The purpose of this study was to elucidate the role of the superior thyroid artery in intra-arterial infusion chemotherapy for laryngeal and hypopharyngeal cancers.
  • Thirty-nine patients with laryngeal cancer and 29 patients with hypopharyngeal cancer underwent intra-arterial infusion chemotherapy.
  • We performed a retrospective analysis of the feeding arteries confirmed by computed tomography during selective arteriography and compared the results with the extent of the tumors.
  • In 14 of 39 laryngeal and 15 of 29 hypopharyngeal cancers, the tumor did not cross the midline (group 1).
  • In the remaining 25 and 14 cancers, respectively, the tumor crossed the midline or located in the center (group 2).
  • For 13 of 14 laryngeal and 7 of 15 hypopharyngeal cancers in group 1 and for 6 of 25 laryngeal cancers in group 2, the entire tumor was contrast enhanced by the ipsilateral superior thyroid and/or superior laryngeal artery.
  • For 12 of 25 laryngeal and 1 of 14 hypopharyngeal cancers in group 2, the entire tumor was contrast enhanced by the bilateral superior thyroid artery.
  • For the other patients, infusion via the other arterial branches such as the inferior thyroid and the lingual arteries were needed to achieve contrast enhancement of the entire tumor.
  • Superselective intra-arterial chemotherapy for laryngeal cancer from the superior thyroid artery is appropriate, whereas that for hypopharyngeal cancer is less sufficient.
  • To accomplish contrast enhancement of the entire tumor, additional intra-arterial infusion from other arteries such as the inferior thyroid artery is often necessary.
  • [MeSH-major] Arteries / anatomy & histology. Hypopharyngeal Neoplasms / blood supply. Infusions, Intra-Arterial / methods. Laryngeal Neoplasms / blood supply
  • [MeSH-minor] Aged. Angiography. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Femoral Artery / radiography. Humans. Male. Middle Aged. Retrospective Studies. Thyroid Gland / blood supply. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16528625.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


36. Rapoport A, Botelho RA, Souza RP, Cavalcanti SM, Furlam S, Tornin Ode S, Souza TR: The importance of pre-epiglottis space invasion in the treatment planning of larynx and hypopharynx cancer. Braz J Otorhinolaryngol; 2008 Jan-Feb;74(1):74-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of pre-epiglottis space invasion in the treatment planning of larynx and hypopharynx cancer.
  • AIM: The aim of this study was to evaluate inter-observer and intra-observer agreement by means of computed tomography analysis regarding the involvement of the pre-epiglottis space (PES) from carcinoma of the upper aerodigestive tract and its relation with therapeutic planning.
  • MATERIALS AND METHODS: Retrospective study of ninety-five computed tomography exams of patients with squamous cell carcinoma, from 1990 to 2004, were selected and evaluated; 87 were males and eight females, with ages ranging from 32 to 73 years.
  • No patient had received any previous treatment up to the moment of imaging examination, such as surgery, chemotherapy or radiotherapy.
  • CONCLUSIONS: After a general Kappa Index of 0.72, the results suggest a substantial agreement in the involvement of the PES by means of computed tomography analysis.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Epiglottis / pathology. Hypopharyngeal Neoplasms / pathology. Laryngeal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Observer Variation. Reproducibility of Results. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392505.001).
  • [ISSN] 1808-8694
  • [Journal-full-title] Brazilian journal of otorhinolaryngology
  • [ISO-abbreviation] Braz J Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


37. Rudat V, Wannenmacher M: Role of multimodal treatment in oropharynx, larynx, and hypopharynx cancer. Semin Surg Oncol; 2001 Jan-Feb;20(1):66-74
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for hypopharynx cancer .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of multimodal treatment in oropharynx, larynx, and hypopharynx cancer.
  • Due to recent advances in radiation fractionation, radiochemotherapy, and conservative surgical techniques, the concept of multimodal therapy in head and neck cancer is currently changing.
  • The recently published RTOG Phase III trial 9003, with 1,113 patients accrued, showed that hyperfractionation and accelerated fractionation with concomitant boost are more efficacious than standard fractionation for locally-advanced head and neck cancer.
  • Three meta-analyses have suggested that the impact of chemotherapy in head and neck cancer is small but is highly associated with the timing of therapy.
  • Concomitant administration of radiation therapy and chemotherapy led to an absolute benefit in 5-year survival of about 10%.
  • This finding has been further supported by recently published randomized prospective trials comparing concomitant radiochemotherapy with radiotherapy alone in advanced head and neck cancer.
  • Radiochemotherapy should be considered an accepted standard of care in cancers of the oropharynx, particularly for patients with locally-advanced disease who have a good performance status.
  • Two randomized studies conducted by the Department of Veterans' Affairs and the EORTC, with a total of 534 patients accrued, showed that induction chemotherapy followed by radiotherapy of responders yields survival rates equal to those of total laryngectomy with postoperative radiotherapy.
  • After 4 years, one-half to two-thirds of survivors of the chemotherapy arm retained a functional larynx.
  • Larynx preservation using induction chemotherapy can now be regarded as feasible but still investigational.
  • More clinical and laboratory research is required to further evaluate the different treatment options of the multimodality concept, and to develop prognostic models that will allow individualization of the therapy.
  • [MeSH-major] Combined Modality Therapy. Hypopharyngeal Neoplasms / therapy. Laryngeal Neoplasms / therapy. Oropharyngeal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11291134.001).
  • [ISSN] 8756-0437
  • [Journal-full-title] Seminars in surgical oncology
  • [ISO-abbreviation] Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 65
  •  go-up   go-down


38. Endo S, Suzuki S, Tsuji K, Nomura Y, Noguchi Y, Kida A, Saito T, Tanaka Y: [Concurrent chemoradiotherapy for advanced hypopharyngeal cancer]. Nihon Jibiinkoka Gakkai Kaiho; 2005 Oct;108(10):980-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concurrent chemoradiotherapy for advanced hypopharyngeal cancer].
  • INTRODUCTION: Chemotherapy has been shown to be most effective when delivered concurrently with radiation for the patients with advanced stage tumors.
  • PATIENTS AND METHODS: Thirty-nine patients with advanced hypopharyngeal cancer received one or two cycles of intravenous administration of CDDP (80-100 mg/m2) followed by 120-hour continuous infusion of 5-FU (800-1000 mg/m2), and concomitant radiotherapy (200 cGy/day x 20-35 fractions) during the period from December, 1993 through December, 2001.
  • Until 1999 definitive surgery was planed in almost all the patients, however, primary tumors had pathologically disappeared in eleven out of the 20 (55%) of the surgical specimens.
  • Based on the result, definitive surgery was reserved for residual or recurrent tumors afterwards.
  • RESULTS: The complete response (CR) rates according to the T factor were 100% (1/1) for T1, 86% (6/7) for T2, 67% (2/3) for T3, and 50% (14/28) for T4, respectively.
  • Two cycles of chemotherapy yielded a significantly higher CR rate than that of one cycle (P = 0.0371).
  • [MeSH-major] Hypopharyngeal Neoplasms / therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285613.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


39. Matsutani T, Sasajima K, Kobayashi Y, Suzuki S, Maruyama H, Miyamoto M, Yokoyama T, Sugiura A, Matsushita A, Yanagi K, Matsuda A, Arai H, Nishi Y, Wakabayashi H, Tajiri T: [A case of double advanced cancer with esophageal and hypopharyngeal carcinoma responding completely to combination chemotherapy of docetaxel/5-fluorouracil and nedaplatin with radiation]. Gan To Kagaku Ryoho; 2009 May;36(5):835-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of double advanced cancer with esophageal and hypopharyngeal carcinoma responding completely to combination chemotherapy of docetaxel/5-fluorouracil and nedaplatin with radiation].
  • The diagnosis was double cancer with hypopharyngeal and esophageal carcinoma from upper gastrointestinal endoscopic examination.
  • Pathological examinations of the double cancer revealed moderately-differentiated squamous cell carcinoma.
  • Computed tomography(CT)of the neck and abdomen showed metastases of the right neck and cardiac lymph nodes.
  • Clinical stagings of the double cancer were Stage III (T1, N1, M0)in hypopharyngeal carcinoma and Stage III (T3, N1, M0)in esophageal carcinoma, respectively.
  • He received radiation therapy in combination with chemotherapy using docetaxel(DOC), 5-fluorouracil (5-FU)and nedaplatin(CDGP).
  • After this combination chemoradiation therapy(CRT), the adverse event was grade 2 in leucopenia and grade 2 in gastrointestinal toxicity.
  • Repeated macroscopic and histological examinations after CRT revealed disappearance of the hypopharyngeal and advanced esophageal carcinoma with lymph node metastasis, leading to a complete response(CR).
  • This combination chemotherapy of DOC, 5-FU and CDGP with radiation may well be effective and tolerable for patients with double cancer of hypopharyngeal and esophageal carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / radiotherapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Esophagoscopy. Fluorouracil / therapeutic use. Humans. Male. Neoplasm Staging. Organoplatinum Compounds / therapeutic use. Remission Induction. Taxoids / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19461189.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 15H5577CQD / docetaxel; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


40. Yang L, Chen WK, Guo ZM, Gu MF, Huang HQ, Zhang Q, Yang AK: Long-term survival of induction chemotherapy plus surgery and postoperative radiotherapy in patients with stage IV hypopharyngeal cancer. Anticancer Drugs; 2010 Oct;21(9):872-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival of induction chemotherapy plus surgery and postoperative radiotherapy in patients with stage IV hypopharyngeal cancer.
  • This study was conducted to evaluate the safety, efficacy, and tolerability of induction chemotherapy plus surgery and postoperative radiotherapy in patients with stage IV hypopharyngeal cancer.
  • The patients received two to three cycles of induction chemotherapy before surgery, with cisplatin (100 mg/m(2)) by rapid intravenous (i.v.) infusion over 15-20 min on day 1, bleomycin (10 mg/m(2)) on days 1 and 5, and 5-fluorouracil (800 mg/m(2)/day) by continuous i.v. infusion on days 1 through 5, repeated every 21 days.
  • After completion of two to three courses of induction chemotherapy, 22 cases of CR (complete response) and 16 cases of PR (partial response) in the primary site were confirmed, giving an overall response rate (ORR) of 73.1% [95% confidence interval (CI), 61.1-85.2%].
  • The combined primary tumor site and lymph node response was 17 CRs and 16 PRs, giving an ORR of 63.5% (95% CI, 50.4-76.6%).
  • The median time to progression and overall survival for all the patients were 32 months (95% CI, 7.6-56.4 months) and 36 months (95% CI, 22.3-49.7 months), respectively.
  • The estimate of time to progression and overall survival at 5 years was 24.5% (95% CI, 12.5-36.5%) and 35.9% (95% CI, 23.2-48.6%), respectively.
  • In conclusion, induction chemotherapy plus surgery and postoperative radiotherapy is a treatment modality that is tolerated with encouraging activity and survival outcome in patients with stage IV hypopharyngeal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hypopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Combined Modality Therapy. Disease Progression. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant / methods. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20836197.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


41. Lee NY, O'Meara W, Chan K, Della-Bianca C, Mechalakos JG, Zhung J, Wolden SL, Narayana A, Kraus D, Shah JP, Pfister DG: Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys; 2007 Oct 1;69(2):459-68
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers.
  • PURPOSE: To perform a retrospective review of laryngeal/hypopharyngeal carcinomas treated with concurrent chemotherapy and intensity-modulated radiotherapy (IMRT).
  • METHODS AND MATERIALS: Between January 2002 and June 2005, 20 laryngeal and 11 hypopharyngeal carcinoma patients underwent IMRT with concurrent platinum-based chemotherapy; most patients had Stage IV disease.
  • The prescription of the planning target volume for gross, high-risk, and low-risk subclinical disease was 70, 59.4, and 54 Gy, respectively.
  • Grade 2 mucositis or higher occurred in 48% of patients, and all experienced Grade 2 or higher pharyngitis during treatment.
  • Xerostomia continued to decrease over time from the end of RT, with none complaining of Grade 2 toxicity at this analysis.
  • The 2-year post-treatment percutaneous endoscopic gastrostomy-dependency rate for those with hypopharyngeal and laryngeal tumors was 31% and 15%, respectively.
  • CONCLUSION: These preliminary results have shown that IMRT achieved encouraging locoregional control of locoregionally advanced laryngeal and hypopharyngeal carcinomas.
  • Xerostomia improved over time.
  • Pharyngoesophageal stricture with percutaneous endoscopic gastrostomy dependency remains a problem, particularly for patients with hypopharyngeal carcinoma and, to a lesser extent, those with laryngeal cancer.
  • [MeSH-major] Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy / methods. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Survival Rate

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493769.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


42. Leu YS, Hsiao HT, Chang YC, Yang CC, Lee JC, Chen YJ, Chang YF: Ileocolic free flap reconstruction, concomitant chemotherapy and radiotherapy and assessment of speech and swallowing function during management of advanced cancer of the larynx and hypopharynx: preliminary report. Acta Otolaryngol; 2005 Jun;125(6):642-6
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ileocolic free flap reconstruction, concomitant chemotherapy and radiotherapy and assessment of speech and swallowing function during management of advanced cancer of the larynx and hypopharynx: preliminary report.
  • CONCLUSION: The new technique of ileocolic free flap reconstruction provides a better quality of life in terms of swallowing and speech for patients who have undergone laryngopharyngectomy with concomitant chemotherapy and radiotherapy (CCRT).
  • MATERIAL AND METHODS: This was a follow-up study of 12 patients with advanced (stages III, IVA and IVB) laryngeal and hypopharyngeal cancer who underwent major surgery, CCRT (with one exception) and ileocolic free flap reconstruction.
  • Eleven patients were diagnosed with hypopharyngeal cancer and one with laryngeal cancer.
  • [MeSH-major] Colon / transplantation. Deglutition / physiology. Hypopharyngeal Neoplasms / surgery. Ileocecal Valve / transplantation. Laryngeal Neoplasms / surgery. Neoadjuvant Therapy. Reconstructive Surgical Procedures. Speech / physiology. Surgical Flaps
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Cause of Death. Follow-Up Studies. Humans. Laryngectomy / rehabilitation. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Pharyngectomy / rehabilitation. Quality of Life. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16076714.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


43. Urba SG, Moon J, Giri PG, Adelstein DJ, Hanna E, Yoo GH, Leblanc M, Ensley JF, Schuller DE: Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial. J Clin Oncol; 2005 Jan 1;23(1):88-95
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial.
  • PURPOSE: The Southwest Oncology Group designed a phase II trial for patients with base of tongue or hypopharyngeal cancer to evaluate the complete histologic response rate at the primary site after induction chemotherapy followed by chemoradiotherapy for responders.
  • PATIENTS AND METHODS: Fifty-nine eligible patients were enrolled; 37 had base of tongue cancer, and 22 had hypopharynx cancer.
  • Induction chemotherapy was two cycles of cisplatin 100 mg/m(2) and fluorouracil 1,000 mg/m(2)/d for 5 days.
  • Patients who had a greater than 50% response at the primary site were treated with radiation 72Gy and concurrent cisplatin 100 mg/m(2) for three cycles.
  • RESULTS: Forty-five patients (76%) had a greater than 50% response at the primary after induction chemotherapy; 43 went on to receive definitive chemoradiotherapy.
  • Thirty-two patients (54%) achieved a histologic complete response at the primary site, and an additional nine patients had a complete clinical response, but biopsy was not done.
  • Seventy-five percent of patients did not require surgery at the primary tumor site.
  • CONCLUSION: Patients with base of tongue or hypopharyngeal cancer treated with this regimen of induction chemotherapy followed by definitive chemoradiotherapy have a good rate of organ preservation without compromise of survival.
  • [MeSH-major] Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / therapy. Tongue Neoplasms / pathology. Tongue Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Radiotherapy Dosage. Salvage Therapy

  • Genetic Alliance. consumer health - Tongue cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15625363.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03096; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA27057; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA37981; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA58416; United States / NCI NIH HHS / CA / CA58686; United States / NCI NIH HHS / CA / CA74647
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


44. Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L, Hupperets P, Barzan L, de Raucourt D, Chevalier D, Licitra L, Lunghi F, Stupp R, Lacombe D, Bogaerts J, Horiot JC, Bernier J, Vermorken JB, EORTC Head and Neck Cancer Cooperative Group, EORTC Radiation Oncology Group: Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst; 2009 Feb 04;101(3):142-52
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy.
  • BACKGROUND: Both induction chemotherapy followed by irradiation and concurrent chemotherapy and radiotherapy have been reported as valuable alternatives to total laryngectomy in patients with advanced larynx or hypopharynx cancer.
  • We report results of the randomized phase 3 trial 24954 from the European Organization for Research and Treatment of Cancer.
  • METHODS: Patients with resectable advanced squamous cell carcinoma of the larynx (tumor stage T3-T4) or hypopharynx (T2-T4), with regional lymph nodes in the neck staged as N0-N2 and with no metastasis, were randomly assigned to treatment in the sequential (or control) or the alternating (or experimental) arm.
  • In the sequential arm, patients with a 50% or more reduction in primary tumor size after two cycles of cisplatin and 5-fluorouracil received another two cycles, followed by radiotherapy (70 Gy total).
  • In the alternating arm, a total of four cycles of cisplatin and 5-fluorouracil (in weeks 1, 4, 7, and 10) were alternated with radiotherapy with 20 Gy during the three 2-week intervals between chemotherapy cycles (60 Gy total).
  • The Kaplan-Meier method was used to obtain time-to-event data.
  • RESULTS: The 450 patients were randomly assigned to treatment (224 to the sequential arm and 226 to the alternating arm).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Chemotherapy, Adjuvant / methods. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Laryngectomy. Radiotherapy, Adjuvant / methods
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Disease-Free Survival. Europe. Female. Fibrosis / etiology. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Laryngeal Edema / etiology. Male. Middle Aged. Mucositis / etiology. Neoplasm Staging. Patient Selection. Radiotherapy Dosage. Recovery of Function. Remission Induction. Research Design. Salvage Therapy / methods. Treatment Failure. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Biometrics. 1975 Mar;31(1):103-15 [1100130.001]
  • [Cites] Biometrics. 1979 Sep;35(3):549-56 [497341.001]
  • [Cites] Cancer. 1983 Apr 15;51(8):1353-5 [6681726.001]
  • [Cites] Cancer. 1984 Sep 1;54(5):811-4 [6204738.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] N Engl J Med. 1992 Oct 15;327(16):1115-21 [1302472.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 16;86(4):265-72 [8158680.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] Oral Oncol. 1998 May;34(3):224-8 [9692058.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Oncologist. 2006 Feb;11(2):146-51 [16476835.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1695-704 [17960012.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1705-15 [17960013.001]
  • [CommentIn] J Natl Cancer Inst. 2009 Feb 4;101(3):129-31 [19176460.001]
  • (PMID = 19176454.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00002839
  • [Grant] United States / NCI NIH HHS / CA / 2U10 CA11488-25; United States / NCI NIH HHS / CA / 5U10 CA11488-37
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2724854
  • [Investigator] de Montreuil B; Bensadoun RJ; Buter J; Coche-Dequeant B; Degardin M; Dehesdin D; Duvillard C; Kutem A; Langendiijk JA; Rame JP; Truc G; van den Weynaert D
  •  go-up   go-down


45. Kohmura T, Hasegawa Y, Matsuura H, Terada A, Takahashi M, Nakashima T: Clinical analysis of multiple primary malignancies of the hypopharynx and esophagus. Am J Otolaryngol; 2001 Mar-Apr;22(2):107-10
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical analysis of multiple primary malignancies of the hypopharynx and esophagus.
  • We reviewed cases of multiple primary squamous cell carcinomas of the hypopharynx and esophagus with regard to their frequency, incidence, and prognosis.
  • PATIENTS AND METHODS: We reviewed 104 cases of hypopharyngeal cancer to determine (1) if and when esophageal cancer occurred, (2) the classification of multiple tumors as metachronous or synchronous, and (3) tumor histology.
  • RESULTS: In most cases of the metachronous type, esophageal cancer followed hypopharyngeal cancer within less than 3 years.
  • Most cases of hypopharyngeal cancer were at an advanced stage, in contrast to esophageal cancer, which were all early stage.
  • These cases had a poor prognosis despite various treatments causing local disease to be well controlled.
  • Endoscopic esophageal mucosal resection was found to be an effective treatment for esophageal cancer, especially in superficial types.
  • CONCLUSIONS: The prognosis and mild systemic damage after endoscopic esophageal mucosal resection compare favorably with surgery, radiation, or systemic chemotherapy.
  • [MeSH-major] Esophageal Neoplasms / pathology. Hypopharyngeal Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Esophagus / pathology. Esophagus / surgery. Humans. Hypopharynx / pathology. Hypopharynx / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11283824.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


46. Miyahara H, Yane K, Naito K: [A case of posterior wall cancer of the hypopharynx treated with docetaxel followed by radiation]. Gan To Kagaku Ryoho; 2003 Aug;30(8):1139-42
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of posterior wall cancer of the hypopharynx treated with docetaxel followed by radiation].
  • We treated a 67-year-old female with hypopharyngeal cancer (T2N0) in the posterior wall, who had a complete response after two cycles of chemotherapy with docetaxel followed by radiation.
  • Five years after this therapy she has had no recurrence and no metastasis, with preserved laryngeal framework and function.
  • Docetaxel is useful for treating early head and neck cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Carcinoma, Squamous Cell / therapy. Hypopharyngeal Neoplasms / therapy. Paclitaxel / administration & dosage. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans

  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12938269.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


47. Ampil F, Mills G, Burton G, Malik A, Krishnamsetty RM: Successful treatment of head and neck cancer involving the prevertebral fascia. South Med J; 2004 Nov;97(11):1126-7
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of head and neck cancer involving the prevertebral fascia.
  • Chemotherapy with radiation has become more popular than radiotherapy alone for patients with locally advanced head and neck cancer because of the successful results associated with it.
  • We report the case of a 67-year-old man with hypopharyngeal cancer invading the prevertebral fascia who became free of disease after chemoradiation.
  • This uncommon, positive observation supports the impression that combined therapy is efficacious in some patients with advanced stage carcinoma of the upper aerodigestive tract.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Fascia / pathology. Head and Neck Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15586610.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


48. Nakamura K, Shioyama Y, Sasaki T, Ohga S, Saku M, Urashima Y, Yoshitake T, Nakashima T, Kuratomi Y, Komune S, Terashima H, Honda H: Chemoradiation therapy with or without salvage surgery for early squamous cell carcinoma of the hypopharynx. Int J Radiat Oncol Biol Phys; 2005 Jul 1;62(3):680-3
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiation therapy with or without salvage surgery for early squamous cell carcinoma of the hypopharynx.
  • PURPOSE: Early squamous cell carcinoma of the hypopharynx is a rare clinical entity.
  • Our objective was to analyze the outcome of patients with early hypopharyngeal cancer treated with curative radiotherapy or the combination of preoperative radiotherapy with surgery.
  • METHODS AND MATERIALS: Forty-three patients with Stage I-II hypopharyngeal cancer were initially treated with 30-40 Gy of irradiation with or without chemotherapy.
  • Thirty-two patients (74.4%) who demonstrated a complete response continued to receive further radiotherapy, with a median total dose of 61.2 Gy.
  • The disease-specific survival rates according to the T-category were 100% for patients with T1 disease and 87.2% for patients with T2 disease (p = 0.32).
  • Twenty patients (46.5%) had synchronous or metachronous cancers.
  • Four patients died of hypopharyngeal cancer, and 5 died of second-primary esophageal cancer.
  • CONCLUSIONS: A majority of patients with early hypopharyngeal cancer was curable.
  • However, second malignancies influenced the overall outcome of patients with early hypopharyngeal cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Hypopharyngeal Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Laryngectomy. Male. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary. Pharyngectomy. Radiotherapy Dosage. Salvage Therapy. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936545.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


49. Yoshimura R, Kagami Y, Ito Y, Asai M, Mayahara H, Sumi M, Itami J: Outcomes in patients with early-stage hypopharyngeal cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys; 2010 Jul 15;77(4):1017-23
Genetic Alliance. consumer health - Hypopharyngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes in patients with early-stage hypopharyngeal cancer treated with radiotherapy.
  • PURPOSE: To analyze the outcome in patients with early-stage hypopharyngeal cancer (HPC) who were treated with radiotherapy (RT).
  • METHODS AND MATERIALS: Between February 1988 and February 2007, 77 patients with Stage I or Stage II HPC underwent definitive RT in the Division of Radiation Oncology at the National Cancer Center Hospital.
  • The survival rates were not affected by the patient characteristics or treatment factors, but the RT field was significantly correlated with local control in a multivariate analysis.
  • CONCLUSION: RT is an appropriate treatment method for early-stage HPC.
  • However, because synchronous or metachronous malignancies occur at a relatively high frequency, careful follow-up and the early detection of such malignancies are critical.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / mortality. Radiotherapy Dosage. Salvage Therapy. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19910141.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Nakagawa T, Otsuki N, Masai Y, Sasaki R, Tsukuda M, Nibu K: Additive effects of oral fluoropyrimidine derivative S-1 and radiation on human hypopharyngeal cancer xenografts. Acta Otolaryngol; 2008 Aug;128(8):936-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additive effects of oral fluoropyrimidine derivative S-1 and radiation on human hypopharyngeal cancer xenografts.
  • CONCLUSION: The results presented here provide evidence of the enhancing effect of oral fluoropyrimidine derivative S-1 in concomitant chemoradiotherapy for head and neck cancer and further insights into its biological mechanism.
  • OBJECTIVE: To investigate the additive effect of S-1 and radiation for human hypopharyngeal cancer.
  • MATERIALS AND METHODS: Nude mice bearing hypopharyngeal cancer cells (H891) were used for an in vivo model.
  • S-1 was administered at a volume of 0.01 mg/g body weight per mouse for 14 days, and tumors were irradiated with 2.0 Gy on days 1 and 8.
  • The growth of tumors in each group was measured and, after completion of the treatment, a focused DNA array was used to determine mRNA expression levels in the tumors of 132 genes related to 5-fluorouracil (5-FU), radiation or carcinogenesis.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Oxonic Acid / administration & dosage. Tegafur / administration & dosage
  • [MeSH-minor] Administration, Oral. Animals. Combined Modality Therapy. Drug Combinations. Fluorouracil / administration & dosage. Humans. Male. Mice. Mice, Nude. Tumor Burden. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18607998.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; U3P01618RT / Fluorouracil
  •  go-up   go-down


51. Dietz A, Nollert J, Eckel H, Volling P, Schröder M, Staar S, Conradt C, Helmke B, Dollner R, Müller RP, Wannenmacher M, Weidauer H, Rudat V: [Organ preservation in advanced laryngeal and hypopharyngeal carcinoma by primary radiochemotherapy. Results of a multicenter phase II study]. HNO; 2002 Feb;50(2):146-54
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Organ preservation in advanced laryngeal and hypopharyngeal carcinoma by primary radiochemotherapy. Results of a multicenter phase II study].
  • INTRODUCTION: Regarding the promising results of international trials we conducted the first German prospective multicentre phase II trial for organ preservation with primary simultaneous chemoradiation in advanced laryngeal and hypopharyngeal cancer.
  • PATIENTS AND METHODS: 28 of 30 recruited patients suffering from stage II and III (UICC) laryngeal and hypopharyngeal cancer were treated with primary simultaneous chemoradiation within an organ preservation program and monitored in follow-up of one year.
  • Exclusion criteria included tumor infiltration of the laryngeal cartilage, bilateral neck nodes (N2c) and need for flap reconstruction in case of laryngectomy.
  • The protocol included an accelerated concomitant boost chemoradiation (66 Gy) with Carboplatinum (70 mg/m2 1st and 5th week) and a restaging procedure one month after therapy.
  • Of these 20 patients 3 developed pulmonary metastases, 1 secondary primary carcinoma of the lung and 3 neck metastases which needed neck dissections.
  • The other patients showed in 4 cases relapsing tumor which was indicated for laryngectomy.
  • One patient needed tracheotomy because of persisting edema and 2 patients died due to tumor progress.
  • Further studies should focus on the improvement of patient selection which could be realized by induction Chemotherapy (using new components like taxan) and/or use of prediction factors such as tumor volume and hemoglobin levels.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Hypopharyngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / radiotherapy. Laryngectomy. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose Fractionation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] HNO. 2002 Feb;50(2):109-13 [12080620.001]
  • (PMID = 12080625.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


52. Małecki K, Gliński B, Mucha-Małecka A, Ryś J, Kruczak A, Roszkowski K, Urbańska-Gąsiorowska M, Hetnał M: Prognostic and predictive significance of p53, EGFr, Ki-67 in larynx preservation treatment. Rep Pract Oncol Radiother; 2010;15(4):87-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic and predictive significance of p53, EGFr, Ki-67 in larynx preservation treatment.
  • BACKGROUND: The optimal management of advanced laryngeal and hypopharyngeal cancers (L&HC) must involve consideration of both survival and functional effect of the given treatment approach.
  • Despite over two decades of investigations of several treatment options, including surgery, radiotherapy, chemotherapy or some combinations thereof, little consensus exists as to which treatment offers the best survival, together with functional speech and swallowing.
  • AIM: To determine predictive and prognostic value of p53, EGFr, Ki-67 in patients with advanced laryngeal and hypopharyngeal cancer, treated with larynx preservation intent.
  • MATERIALS AND METHODS: Thirty-three patients received 2-3 cycles of induction chemotherapy (ICHT) consisting of cisplatin and fluoruracil and underwent subsequent radical radiotherapy.
  • The 5-year larynx preservation rate was 68% in responders to ICHT compared to 21% in non-responders (p = 0.02).
  • Neither p53 nor Ki-67 have predictive and prognostic value in larynx preservation treatment.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24376930.001).
  • [ISSN] 1507-1367
  • [Journal-full-title] Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznań and Polish Society of Radiation Oncology
  • [ISO-abbreviation] Rep Pract Oncol Radiother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC3863202
  • [Keywords] NOTNLM ; EGFr / Induction chemotherapy / Ki-67 / Larynx preservation / p53
  •  go-up   go-down


53. Bastit L, Blot E, Debourdeau P, Menard J, Bastit P, Le Fur R: Influence of the delay of adjuvant postoperative radiation therapy on relapse and survival in oropharyngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys; 2001 Jan 1;49(1):139-46

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of the delay of adjuvant postoperative radiation therapy on relapse and survival in oropharyngeal and hypopharyngeal cancers.
  • PURPOSE: To determine whether the delay between surgery and the beginning of radiation therapy influences survival or the risk of local-regional relapse in oropharyngeal or hypopharyngeal squamous cell carcinomas.
  • METHODS AND MATERIALS: From 2052 patients referred to the Henri Becquerel Center for the radiation therapy of an oropharyngeal or hypopharyngeal cancer between January 1, 1981 and December 31, 1992, 420 were included in a retrospective study.
  • Exclusion criteria were another cancer, metastasis, incomplete resection, lack of homolateral lymph node resection, or previous chemotherapy.
  • Radiation therapy delivered 45 to 75 Gy on initial location and lymph node.
  • RESULTS: The delay between surgery and radiation therapy was not found to be a significant prognostic factor for survival or risk of local-regional relapse.
  • In terms of local-regional relapse only, age was a prognostic factor (p = 0.048), and a trend was noted for tumor emboli in vessels or nerves (p = 0.061).
  • CONCLUSION: In patients with oropharyngeal or hypopharyngeal squamous cell carcinoma, the delay between surgical procedure and radiation therapy does not influence survival or risk of local-regional relapse.
  • Radiation therapy might be subjected to complete healing in these patients.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11163507.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Ikeda Y, Tsukuda M, Ishitoya J, Arai Y, Matsuda H, Katori H, Taguchi T, Yoshida T, Ono M, Sakuma Y, Yagisawa M, Saito N: Four cases of simultaneous triple primary cancers of the hypopharynx, esophagus, and stomach. Otolaryngol Head Neck Surg; 2005 May;132(5):788-93
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four cases of simultaneous triple primary cancers of the hypopharynx, esophagus, and stomach.
  • OBJECTIVE: To study the efficacy of intensive chemotherapy for simultaneous triple primary cancers of the hypopharynx, esophagus, and stomach.
  • METHODS: From April 2000 to March 2002, we treated 4 patients who had simultaneous triple primary cancers, including hypopharyngeal, esophageal, and gastric carcinomas.
  • These 4 patients were designated as the objects for analysis, and the treatment modality for simultaneous multiple primary cancer cases was examined.
  • RESULTS: In 3 of 4 patients, all 3 primary cancers could be controlled by intensive induction chemotherapy and concurrent chemoradiotherapy for hypopharyngeal cancer and by endoscopic mucosal resection or argon plasma coagulation for esophageal and gastric carcinomas.
  • CONCLUSIONS: In the treatment modality for simultaneous multiple primary cancers, including head and neck cancer, it is important to select intensive systemic chemotherapy and decide the order for treating each primary lesion in consideration of each patient's curability and prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Gastric Mucosa. Humans. Male. Middle Aged. Neoplasms, Multiple Primary. Prognosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15886636.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Kogashiwa Y, Yamauchi K, Nagafuji H, Matsuda T, Tsubosaka T, Tsutsumi T, Karaho T, Kohno N: Concurrent chemoradiotherapy for organ function preservation in advanced patients with hypopharyngeal and laryngeal cancer. Oncol Rep; 2009 Nov;22(5):1163-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiotherapy for organ function preservation in advanced patients with hypopharyngeal and laryngeal cancer.
  • Preservation of the larynx is the most critical factor influencing quality of life in the treatment of head and neck cancer.
  • This clinical study focuses on laryngeal function-preserving chemoradiotherapy for locally advanced hypopharyngeal and laryngeal cancer.
  • Thirty-two resectable cases with histologically proven squamous cell carcinoma undergoing function-preserving therapy were examined.
  • Induction chemotherapy comprised cisplatin and 5-fluorouracil, and another cycle of chemotherapy was performed for responders.
  • Chemoradiotherapy comprised conventional irradiation and weekly chemotherapy (nedaplatin plus docetaxel).
  • Non-responder patients were excluded from further chemotherapy and were changed to other surgical treatment.
  • Three patients were non-responders for induction chemotherapy, and 29 patients were treated with chemoradiotherapy.
  • Initial larynx preservation rate with these treatment strategies was 93.8%.
  • This study provides a new concept for laryngeal function-preserving treatment that should be considered for locally advanced laryngeal and hypopharyngeal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Hypopharyngeal Neoplasms / therapy. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Genetic Alliance. consumer health - Laryngeal cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787235.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


56. Yoshida T, Tokashiki R, Itoh H, Nakamura K, Hiramatsu H, Tsukahara K, Shimizu S, Takada D, Okamoto I, Abe K, Suzuki M: A phase I-II study of bi-weekly docetaxel combined with radiation therapy for patients with cancer of the larynx/hypopharynx. Jpn J Clin Oncol; 2007 Sep;37(9):641-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I-II study of bi-weekly docetaxel combined with radiation therapy for patients with cancer of the larynx/hypopharynx.
  • METHODS: Patients with T2N0-1M0, T3N0M0 hypopharyngeal cancer or T2N0-1M0, T3N0-1M0 larynx cancer were enrolled.
  • Docetaxel was administered bi-weekly (days 1, 15, 29) from the first day of radiotherapy, while 2 Gy/day of radiation was given on 5 days weekly from day 1, reaching a total of 60 Gy in 30 fractions.
  • Treatment was completed without interruption in 24 patients, with a protocol implementation rate of 96%.
  • The complete response rate was 100% in laryngeal cancer, and 80% in hypopharyngeal cancer, and total (including partial response) overall response rate was 100%.
  • CONCLUSIONS: The chemoradiation therapy using bi-weekly docetaxel is an extremely effective treatment for cancer of the larynx/hypopharynx, provided that it is used for the specified stage of cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Radiation-Sensitizing Agents / administration & dosage. Taxoids / administration & dosage
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Dose Fractionation. Drug Administration Schedule. Female. Humans. Injections, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Treatment Outcome

  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940076.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Radiation-Sensitizing Agents; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


57. Kikuchi D, Iizuka T, Hoteya S, Miyata Y, Mitani T, Ochiai Y, Sakurada T, Hirano N, Hayashi T, Nakamura M, Yahagi N: [Safe and successful chemoradiotherapy for a patient with cardiac pacemaker and triple cancers]. Gan To Kagaku Ryoho; 2009 Jun;36(6):1025-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Safe and successful chemoradiotherapy for a patient with cardiac pacemaker and triple cancers].
  • The patient was a 70-year-old male with superficial hypopharyngeal cancer and advanced cancers of the esophagus and stomach.
  • Further examination showed esophageal cancer had metastasized to the cervical lymph nodes and invaded the trachea.
  • Electrocardiogram was monitored during the treatment.
  • S-1 was selected as a concomitant chemotherapy.
  • [MeSH-major] Esophageal Neoplasms / therapy. Hypopharyngeal Neoplasms / therapy. Neoplasms, Multiple Primary / therapy. Pacemaker, Artificial. Stomach Neoplasms / therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Combined Modality Therapy. Drug Combinations. Electrocardiography. Humans. Male. Oxonic Acid / administration & dosage. Sick Sinus Syndrome / therapy. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Pacemakers and Implantable Defibrillators.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542730.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


58. Okumura Y, Ryotokuji T, Miura A, Kato T, Tomemori T, Mitsuhashi T, Monma K, Izumi Y: [Successfully treated case of hypopharyngeal and cervical esophageal squamous cell carcinoma with laryngeal preservation]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2385-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successfully treated case of hypopharyngeal and cervical esophageal squamous cell carcinoma with laryngeal preservation].
  • He was diagnosed as hypopharyngeal cancer (cT2N1M0, cStage III) and cervical esophageal cancer (cT2N1M0, cStage III).
  • Firstly he was administered 5-FU, DXR and CDDP as induction chemotherapy.
  • The response evaluation was PR according to RECIST criteria.
  • After the induction chemotherapy, he was treated with chemoradiotherapy (64.8 Gy/54 fr, concurrent with weekly DOC 10 mg/m2).
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy. Hypopharyngeal Neoplasms / therapy. Neoplasms, Multiple Primary / therapy. Salvage Therapy
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Fluorouracil / administration & dosage. Humans. Lymph Node Excision. Male. Middle Aged. Neck

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224581.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


59. Shimane T, Mori T, Ono T, Egawa S, Furuya A, Kobayashi S, Sanbe T, Suzaki H: [Effects of concurrent S-1, nedaplatin/radiation therapy for 5 cases of head and neck cancer with esophageal carcinoma]. Gan To Kagaku Ryoho; 2010 Jul;37(7):1349-52
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of concurrent S-1, nedaplatin/radiation therapy for 5 cases of head and neck cancer with esophageal carcinoma].
  • It is not rare to observe multiple cancers in cases of head and neck carcinoma.
  • Such cancers are important factors for deciding the therapeutic strategy.
  • Complications of esophageal cancer are particularly frequent in cases of hypopharyngeal cancer in comparison to other head and neck tumors.
  • At our department, for organ and functional preservation, and radical cure, we have used simultaneous therapy instead of separate therapy for head and neck tumors and esophageal cancer.
  • We have been implementing concurrent S-1, nedaplatin/radiation therapy (hereinafter called SN therapy) for cases of advanced cancer of the head and neck, and we applied the same therapy for cases of head and neck carcinoma with esophageal cancer.
  • The subjects comprised 5 cases of head and neck tumors complicated by esophageal cancer for which therapy was conducted at our department between April 2005 and March 2009.
  • The histologic type was squamous cell carcinoma in all of the cases.
  • There were 2 cases of laryngeal cancer (T3N2cM0, T3N0M0) and 3 cases of hypopharyngeal cancer (T3N2cM0, T4N2cM0, T3N2bM0).
  • As a result, 3 out of the 5 cases have remained cancer-free, and the average observation period was 29. 3 months.
  • One case expired due to an unrelated cause as a result of cardiac disease, while in the remaining case, the tumor did not disappear and the patient died due to the disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Organoplatinum Compounds / therapeutic use. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Combined Modality Therapy. Drug Combinations. Fatal Outcome. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647725.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Organoplatinum Compounds; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 8UQ3W6JXAN / nedaplatin
  •  go-up   go-down


60. Montero EH, Trufero JM, Romeo JA, Terré FC: Comorbidity and prognosis in advanced hypopharyngeal-laryngeal cancer under combined therapy. Tumori; 2008 Jan-Feb;94(1):24-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comorbidity and prognosis in advanced hypopharyngeal-laryngeal cancer under combined therapy.
  • AIMS AND BACKGROUND: The success of combined treatment in head and neck cancer resides largely in its completion, which can be compromised when the patient's general health status is precarious.
  • The objective of this investigation was to study the role of comorbidity as a prognostic factor in a large, homogeneous population affected by locally advanced pharyngeal-laryngeal cancer, under a combined protocol treatment.
  • The a priori hypothesis is that comorbidity strongly conditions overall survival and specific overall survival in these patients and can aid in the selection and individualization of treatments.
  • Of the original 114 patients selected, 15 were withdrawn because the tumor spread to maxillofacial areas, or due to the lack of attendance at the clinic, incomplete clinical data or coexistent primary tumors.
  • The group under analysis consisted of the 99 remaining patients affected by stage III and IV laryngeal and/or hypopharyngeal cancers that had not received previous treatments.
  • In the multivariate analysis, tumor staging, neoadjuvant chemotherapy response and comorbidity (RR = 1.55 and 1.44 for overall and specific overall survival, respectively) present themselves as three prognostic factors independent of overall and specific overall survival.
  • CONCLUSIONS: The role of comorbidity as an independent prognostic factor in patients affected by laryngeal and/or hypopharyngeal cancer treated with chemo-radiotherapy should be taken into account in the tailoring of treatments and the improvement of therapeutic results.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Hypopharyngeal Neoplasms / epidemiology. Laryngeal Neoplasms / epidemiology
  • [MeSH-minor] Combined Modality Therapy. Comorbidity. Follow-Up Studies. Humans. Middle Aged. Prognosis. Retrospective Studies. Spain / epidemiology. Survival Rate

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18468331.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


61. Lièvre A, Blons H, Houllier AM, Laccourreye O, Brasnu D, Beaune P, Laurent-Puig P: Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma. Br J Cancer; 2006 Mar 13;94(5):692-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mitochondrial DNA mutations have been reported in several types of tumours, including head and neck squamous cell carcinoma (HNSCC).
  • The noncoding region of the Displacement-Loop (D-Loop) has emerged as a mutational hotspot and we recently found that they were associated with prognosis and response to 5 fluorouracil (5FU) in colon cancers.
  • In order to evaluate the frequence of D-Loop mutations in a large series of HNSCC and establish correlations with clinicopathologic parameters, we sequenced the D-Loop of 109 HNSCC before a treatment by neoadjuvant 5FU-cisplatin-based chemotherapy and surgery.
  • Then, we correlated these mutations with prognosis and response to chemotherapy.
  • The prevalence of D310 mutations increased significantly with the number of cytosines in the matched normal tissue sequence (P=0.02).
  • Hypopharyngeal cancer was significantly more frequent (P=0.03) and tobacco consumption more important (P=0.01) in the group of patients with D-Loop mutation.
  • The presence of D-Loop mutation was not associated with prognosis or with response to neoadjuvant chemotherapy.
  • These results suggest that D-Loop mutations should be considered as a cancer biomarker that may be useful for the early detection of HNSCC in individuals at risk of this cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / genetics. DNA, Mitochondrial / genetics. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / genetics
  • [MeSH-minor] Cisplatin / administration & dosage. DNA Mutational Analysis. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Predictive Value of Tests. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutat Res. 1999 Jul 30;434(3):177-203 [10486591.001]
  • [Cites] Curr Opin Oncol. 1999 May;11(3):200-3 [10328595.001]
  • [Cites] Head Neck. 2005 Jan;27(1):15-21 [15515158.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3517-25 [15908662.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1504-11 [11745228.001]
  • [Cites] Int J Cancer. 1999 Aug 20;84(4):410-5 [10404095.001]
  • [Cites] Oncogene. 1999 Nov 18;18(48):6641-6 [10597269.001]
  • [Cites] Science. 2000 Mar 17;287(5460):2017-9 [10720328.001]
  • [Cites] Oncogene. 2000 Apr 13;19(16):2060-6 [10803467.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4231-7 [10945635.001]
  • [Cites] Gastroenterology. 2000 Dec;119(6):1808-9 [11187439.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):319-21 [11291064.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Jan;2(1):67-71 [11413468.001]
  • [Cites] Int J Cancer. 2001 Aug 15;93(4):534-8 [11477557.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):5998-6001 [11507041.001]
  • [Cites] Oncogene. 2001 Aug 23;20(37):5195-8 [11526508.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6698-702 [11559538.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7015-9 [11585726.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7623-6 [11606403.001]
  • [Cites] Int J Cancer. 2001 Nov 1;94(3):429-31 [11745425.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):481-7 [11839667.001]
  • [Cites] Oncogene. 2002 May 23;21(23):3780-3 [12032845.001]
  • [Cites] Gastroenterology. 2002 Jun;122(7):2049-63 [12055609.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2260-5 [12114429.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Jun;37(2):186-94 [12696067.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2594-9 [15102660.001]
  • [Cites] Diagn Mol Pathol. 2004 Mar;13(1):26-32 [15163006.001]
  • [Cites] Eur J Cancer Prev. 2004 Jun;13(3):165-72 [15167214.001]
  • [Cites] Science. 2004 Jul 30;305(5684):626-9 [15286356.001]
  • [Cites] Chem Biol Interact. 1987;63(2):157-69 [3664791.001]
  • [Cites] Mutat Res. 1989 Sep;214(1):47-61 [2671701.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1152-5 [8118797.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1156-8 [8118798.001]
  • [Cites] Anticancer Res. 1994 Jul-Aug;14(4A):1489-92 [7979175.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):147-53 [8000993.001]
  • [Cites] Cancer Causes Control. 1996 Mar;7(2):240-52 [8740737.001]
  • [Cites] Cancer Res. 1996 Dec 15;56(24):5692-7 [8971177.001]
  • [Cites] Blood. 1997 Mar 15;89(6):1854-61 [9058704.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 18;235(2):286-90 [9199183.001]
  • [Cites] Nat Genet. 1998 Nov;20(3):291-3 [9806551.001]
  • [Cites] FEBS Lett. 1998 Dec 18;441(2):292-6 [9883902.001]
  • [Cites] Cell Death Differ. 1998 Aug;5(8):694-701 [10200525.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • (PMID = 16495928.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2361200
  •  go-up   go-down


62. Hua H, Liu Q, Han Z, Chen J, Li F, Ding H: [The study on the occult metastases to cervical lymph node in squamous cell carcinoma of the larynx and hypopharynx]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2001 Sep;15(9):391-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The study on the occult metastases to cervical lymph node in squamous cell carcinoma of the larynx and hypopharynx].
  • OBJECTIVE: To study the metastastic regularity of cervical lymph node in squamous cell carcinoma of the larynx and hypopharynx, which will provide some theoretical basis for surgeon to use selective neck dissection (SND) in some patients with carcinoma above.
  • These patients weren't given any treatment (radiotherapy or chemotherapy or surgery in neck) before surgery.
  • Among them, six patients with supraglottic cancer, 1 patient with transglottic cancer and 7 patients with hypopharyngeal cancer.
  • There were no occult metastases to cervical lymph node among 9 patients with glottic cancer.
  • CONCLUSION: The study further prove that metastases to cervical lymph node mainly occur in the ipsilateral level II and level III among patients with carcinoma of the larynx and hypopharynx.
  • According to the risks of occurring occult metastases to cervical lymph node, we suggest applying to ipsilateral or bilateral SND (level II and level III be dissected) among patients with carcinoma of the larynx and hypopharynx which staged T2-T4 N0M0 clinically.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Hypopharyngeal Neoplasms / pathology. Laryngeal Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12541884.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


63. Sanabria A, Domenge C, D'cruz A, Kowalski LP: Organ preservation protocols in developing countries. Curr Opin Otolaryngol Head Neck Surg; 2010 Apr;18(2):83-8
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present review we consider the possible problems associated with the application of organ preservation strategies in developing countries in some critical areas: advanced stage, comorbidities, nutritional status, long distance to travel, availability of chemotherapy and radiotherapy facilities, tolerance, adherence to protocol standards and expertize in performing salvage surgery.
  • Recent publications strongly suggest that chemoradiation should not be indicated in all patients with advanced laryngeal and hypopharyngeal cancer, but that an individualized treatment strategy should be recommended.
  • SUMMARY: Organ preservation treatments depend on factors related to the physician and the institutions providing healthcare, and also on patients and health systems and socioeconomic factors that make it impossible to extrapolate these results.
  • [MeSH-major] Clinical Protocols / standards. Developing Countries. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy. Salvage Therapy / standards. Salvage Therapy / statistics & numerical data
  • [MeSH-minor] Guidelines as Topic. Humans. Neoplasm Invasiveness. Neoplasm Staging. Patient Selection. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216217.001).
  • [ISSN] 1531-6998
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


64. Tamura K, Yoshinaga T, Tanino M, Kimura T, Yamada N, Nishimura M, Fukuda S, Nishihara H, Shindoh M, Tanaka S: Hypopharyngeal squamous cell carcinoma producing both granulocyte colony-stimulating factor and parathyroid hormone-related protein. Pathol Int; 2008 Oct;58(10):652-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypopharyngeal squamous cell carcinoma producing both granulocyte colony-stimulating factor and parathyroid hormone-related protein.
  • Laryngoscopy indicated hypopharyngeal tumor histologically diagnosed as squamous cell carcinoma (SCC).
  • A combination of radiotherapy and chemotherapy was performed for 2 months, and the hypopharyngeal lesion completely regressed.
  • Subsequently, positron emission tomography (PET) showed multiple metastases to several organs including the liver, spine, skull, and thigh.
  • Two months after readmission, the patient died with no success of chemotherapy.
  • At autopsy, the lung tumor was clearly positive for both G-CSF and PTHrP on immunohistostaining.
  • Retrospectively, examination showed that the primary pharyngeal tumor was focally positive for these two cytokines.
  • Thus, a certain population of hypopharyngeal cancer producing G-CSF and PTHrP, spread to various organs and contributed to the rapid progression and poor prognosis.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Granulocyte Colony-Stimulating Factor / blood. Hypopharyngeal Neoplasms / metabolism. Parathyroid Hormone-Related Protein / blood
  • [MeSH-minor] Combined Modality Therapy. Deglutition Disorders / pathology. Fatal Outcome. Female. Humans. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18801086.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


65. Kornek GV, Selzer E: [Organ sparing treatment modalities - which type of treatment for which carcinoma?]. Wien Med Wochenschr; 2008;158(9-10):264-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Organ sparing treatment modalities - which type of treatment for which carcinoma?].
  • [Transliterated title] Organerhaltende Therapiemodalitäten - welche Therapie für welches Karzinom?
  • Radical surgery followed by postoperative radiotherapy is still the most effective treatment option for advanced resectable head and neck cancer.
  • It is therefore of utmost importance to determine the resectability before start of the treatment.
  • For those patients who suffer from unresectable cancer or refuse to undergo surgery, alternatives, such as induction-chemotherapy or radiotherapy plus chemotherapy alone may be offered.
  • Historical studies investigating alternative treatment protocols were conducted almost 20 years ago.
  • These studies demonstrated that in approximately 2/3 of all patients with laryngeal and hypopharyngeal cancer undergoing induction-chemotherapy according to the PF-protocol (cisplatin plus 5-FU as a continuous infusion) and subsequent radiotherapy, larynx preservation without negative impact on overall survival could be achieved.
  • At least three randomized studies have shown a clinical advantage for a treatment combination consisting of docetaxel or paclitaxel plus CDDP/5-FU over a historical control regimen containing CDDP/5-FU alone.
  • This novel combination therefore is currently regarded as the gold-standard for induction-chemotherapy in advanced head and neck cancer patients.
  • A further significant addition to the therapeutic armamentarium for the head and neck radiation oncologist is the recently introduced monoclonal antibody cetuximab.
  • It was found in a randomized landmark study that addition of cetuximab to radiotherapy significantly improves local control as well as overall survival of advanced stage head and neck cancer patients.
  • In light of these recent developments this review discusses the role of organ sparing treatment protocols and different levels of evidence with special consideration of tumor localization.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Chemotherapy, Adjuvant. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Humans. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy. Neoplasm Invasiveness. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted. Randomized Controlled Trials as Topic. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Radiat Oncol. 1998 Oct;8(4):262-9 [9873104.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6 [10601378.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [18270337.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16 [10924966.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1695-704 [17960012.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1705-15 [17960013.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1178-83 [3304610.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):88-95 [15625363.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1310-7 [9552031.001]
  • [Cites] Lancet Oncol. 2006 Jul;7(7):565-74 [16814208.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8636-45 [16275937.001]
  • (PMID = 18560952.001).
  • [ISSN] 0043-5341
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 17
  •  go-up   go-down


66. Watanabe K, Asakage T, Nakao K, Ebihara Y, Fujishiro Y, Okazaki M, Asato H, Sugasawa M: Planned simultaneous cervical skin reconstruction for salvage total pharyngolaryngectomy. Jpn J Clin Oncol; 2008 Mar;38(3):167-71
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Salvage surgery after definitive radiotherapy with or without chemotherapy is still controversial, especially in cases of hypopharyngeal cancer because of the poor prognosis and surgical complications.
  • Both the prolongation of the operation time and of the duration of hospitalization were within acceptable limits.
  • CONCLUSION: Planned cervical skin reconstruction appears to be an appropriate and acceptable procedure with salvage pharyngolaryngectomy to avoid major complications.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Dermatologic Surgical Procedures. Hypopharyngeal Neoplasms / surgery. Laryngectomy / methods. Pharyngectomy / methods. Reconstructive Surgical Procedures
  • [MeSH-minor] Antibiotic Prophylaxis. Aortic Rupture / etiology. Carotid Arteries. Humans. Male. Middle Aged. Neck Dissection. Postoperative Complications. Radiation Injuries / surgery. Reoperation. Salvage Therapy / methods. Skin / radiation effects. Surgical Flaps / adverse effects. Surgical Wound Infection / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18272474.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


67. Kosaka Y, Okuno Y, Tagawa Y, Ueki N, Itoh K, Shinohara S, Kikuchi M: Osteoradionecrosis of the cervical vertebrae in patients irradiated for head and neck cancers. Jpn J Radiol; 2010 Jun;28(5):388-94
MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoradionecrosis of the cervical vertebrae in patients irradiated for head and neck cancers.
  • Osteoradionecrosis (ORN) is one of the common late adverse effects that follow radiation therapy for head and neck cancers.
  • Two patients suffered from secondary osteomyelitis after neoadjuvant chemotherapy followed by definitive concurrent chemoradiation therapy with a hyperfractionated and an accelerated hyperfractionated regimen, respectively.
  • For these patients, the high intensity of treatment was considered the cause of ORN.
  • The third patient underwent concurrent chemoradiation therapy for upper thoracic esophageal cancer and subsequently underwent endoscopic laser resection and radiation therapy for hypopharyngeal cancer.
  • ORN developed in the area of reirradiation.
  • In the future, ORN of cervical vertebrae will increase because metachronous double cancers will increase and opportunities for reirradiation, in turn, will increase.
  • To prevent this, it is necessary to optimize the treatment schedule for radiation therapy, including the total dose, fractionation, and concurrent chemotherapy, and to decrease the volume of cervical vertebrae within the irradiation field.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4893-900 [15520052.001]
  • [Cites] Cancer Treat Rev. 2002 Feb;28(1):65-74 [12027415.001]
  • [Cites] Acta Otolaryngol. 2007 Feb;127(2):194-205 [17364352.001]
  • [Cites] J Neurosurg Spine. 2005 Aug;3(2):159-64 [16370306.001]
  • [Cites] Br J Radiol. 1996 Sep;69(825):847-51 [8983589.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16 [10924966.001]
  • [Cites] Radiother Oncol. 2004 Jul;72(1):1-13 [15236869.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):90-7 [16213108.001]
  • [Cites] Am J Otolaryngol. 1999 Nov-Dec;20(6):408-11 [10609488.001]
  • [Cites] Pathol Oncol Res. 2000;6(1):53-8 [10749589.001]
  • (PMID = 20585930.001).
  • [ISSN] 1867-108X
  • [Journal-full-title] Japanese journal of radiology
  • [ISO-abbreviation] Jpn J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


68. Fujimoto C, Ito K, Iwasaki S, Nakao K, Sugasawa M: Reversible impairment of auditory callosal pathway in 5-fluorouracil-induced leukoencephalopathy: parallel changes in function and imaging. Otol Neurotol; 2006 Aug;27(5):716-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENT: A 58-year-old man with hypopharyngeal cancer who developed 5-fluorouracil-induced leukoencephalopathy.
  • RESULTS: The patient underwent systemic chemotherapy with pirarubicin, cisplatin, and 5-fluorouracil.
  • Fluid-attenuated inversion recovery images showed no abnormal findings at this time.
  • CONCLUSION: By using both functional and imaging modalities, this case study demonstrated, for the first time in a reversible manner, that the auditory callosal pathway runs through the most posterior part of the corpus callosum including the splenium.
  • Diffusion-weighted magnetic resonance imaging was considered useful for early diagnosis of 5-fluorouracil-induced leukoencephalopathy.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Auditory Pathways / drug effects. Dementia, Vascular / chemically induced. Fluorouracil / adverse effects. Hypopharyngeal Neoplasms / drug therapy
  • [MeSH-minor] Corpus Callosum / pathology. Corpus Callosum / physiopathology. Dichotic Listening Tests. Diffusion Magnetic Resonance Imaging. Dominance, Cerebral. Humans. Male. Middle Aged. Recovery of Function. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16691149.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


69. Nakamura K, Shioyama Y, Kawashima M, Saito Y, Nakamura N, Nakata K, Hareyama M, Takada T, Karasawa K, Watanabe T, Yorozu A, Tachibana H, Suzuki G, Hayabuchi N, Toba T, Yamada S: Multi-institutional analysis of early squamous cell carcinoma of the hypopharynx treated with radical radiotherapy. Int J Radiat Oncol Biol Phys; 2006 Jul 15;65(4):1045-50
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-institutional analysis of early squamous cell carcinoma of the hypopharynx treated with radical radiotherapy.
  • PURPOSE: To analyze the outcomes of patients with early hypopharyngeal cancer treated with radical radiotherapy (RT).
  • METHODS AND MATERIALS: Ten institutions combined the data from 115 patients with Stage I-II hypopharyngeal squamous cell carcinoma treated with definitive RT between 1990 and 2001.
  • Conventional fractionation was used in 98 patients and twice-daily RT in 17 patients; chemotherapy was combined with RT in 57 patients.
  • Sixty-five patients (56.5%) had synchronous or metachronous cancers.
  • Of the 115 patients, 19 died of hypopharyngeal cancer, 10 died of second primary cancers, and 14 died of other causes during the study and follow-up periods.
  • CONCLUSIONS: Patients with early hypopharyngeal cancer tended to have a good prognosis after RT.
  • However, second malignancies had an adverse effect on the overall outcomes of patients with early hypopharyngeal cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Combined Modality Therapy. Female. Humans. Laryngectomy. Male. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / pathology. Radiotherapy Dosage. Recurrence. Retrospective Studies. Salvage Therapy. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16682142.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Léon X, Gras JR, Pérez A, Rodríguez J, de Andrés L, Orús C, Quer M: Hypothyroidism in patients treated with total laryngectomy. A multivariate study. Eur Arch Otorhinolaryngol; 2002 Apr;259(4):193-6
MedlinePlus Health Information. consumer health - Hypothyroidism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One of the complications of the treatment of head and neck carcinoma patients is hypothyroidism.
  • The objective of our study was to quantify the prevalence of hypothyroidism in patients with laryngeal or hypopharyngeal cancer treated with a total laryngectomy and to evaluate the importance of different variables in the appearance of hypothyroidism in this group of patients.
  • Sex, initial extension of the tumour, hemithyroidectomy, use of chemotherapy and radiotherapy were variables associated with the appearance of hypothyroidism in the univariate analysis (P < 0.05).
  • When all these variables were included in a multivariate study, only hemithyroidectomy (RR 3,6; CI 95% 1,7-7,2) and combined treatment with radiotherapy (RR 3,4; CI 95% 1,2-9,6) appeared as prognostic factors.
  • In conclusion, hypothyroidism is a frequent complication in patients treated with a total laryngectomy (52%), especially when this treatment includes hemithyroidectomy and/or radiotherapy.
  • We consider that it is important to check the thyroid function periodically in these patients to obtain early diagnosis and appropriate treatment.
  • [MeSH-major] Hypopharyngeal Neoplasms / surgery. Hypothyroidism / etiology. Laryngeal Neoplasms / surgery. Laryngectomy / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12064507.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


71. Saussez S, Cucu DR, Decaestecker C, Chevalier D, Kaltner H, André S, Wacreniez A, Toubeau G, Camby I, Gabius HJ, Kiss R: Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann Surg Oncol; 2006 Jul;13(7):999-1009
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer.
  • BACKGROUND: Eighty percent of hypopharyngeal squamous cell carcinoma patients have advanced stages (III and IV) of the disease, and biological markers are required to predict high-risk head and neck squamous cell carcinoma patients in need of highly aggressive treatments after surgery to improve the survival rate.
  • We analyzed the potential prognostic value of galectin 7 in a series of 81 stage IV hypopharyngeal SCCs because galectin 7 is an emerging marker involved in the epidermal development of pluristratified epithelia and in epidermal cell migration.
  • METHODS: The immunohistochemical expression of galectin 7 was determined on a series of 81 stage IV hypopharyngeal SCCs and was compared with that of galectins 1 and 3.
  • RESULTS: High levels of galectin 7 expression were associated with rapid recurrence rates and dismal prognoses in these 81 stage IV hypopharyngeal SCCs, a feature not observed with galectin 3 and one observed weakly, if at all, with galectin 1.
  • CONCLUSIONS: These data suggest that the immunohistochemical determination of galectin 7 expression in the case of high-risk hypopharyngeal cancers is a meaningful tool to identify patients who should benefit from aggressive postsurgical adjuvant therapy after surgery, including not only radiotherapy, but also chemotherapy.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Galectins / metabolism. Hypopharyngeal Neoplasms / metabolism. Hypopharyngeal Neoplasms / mortality. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Female. Galectin 3 / metabolism. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16788763.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / Galectins; 0 / LGALS7 protein, human
  •  go-up   go-down


72. Al-Herabi AZ: Head and neck oncology experience in Makkah, Saudi Arabia. Saudi Med J; 2009 Oct;30(10):1316-22
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To present our experience in head and neck cancer, and the development of our own local electronic Makkah Head and Neck Database.
  • METHODS: A prospective collection of cases was conducted between October 2007 and November 2008 of patients diagnosed with head and neck cancer within the Department of Otolaryngology, Head and Neck Surgery at Al-Noor Specialist Hospital, Makkah, Kingdom of Saudi Arabia.
  • Sixteen patients (36.4%) had oral cavity cancer, 10 patients (22.7%) had hypopharyngeal cancer, 10 patients (22.7%) had nasopharyngeal cancer, 6 patients (13.6%) had thyroid cancer, and 2 patients (4.5%) had neck secondary-unknown primary.
  • Twenty-four patients (54.5%) were managed primarily by surgery, while 20 patients (45.5%) were managed primarily non-surgically in the form of external beam radiotherapy (XRT), or XRT/Chemotherapy.
  • CONCLUSION: All oncological services of head and neck cancer patients including surgery, radiotherapy, and chemotherapy should be provided in one oncology center, and managed through a standard one channel, namely, the Head and Neck Oncology Board, to achieve standard patient care, adequate follow up, and surveillance.
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / surgery. Male. Mouth Neoplasms / pathology. Mouth Neoplasms / surgery. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Neoplasms, Unknown Primary / pathology. Neoplasms, Unknown Primary / surgery. Saudi Arabia. Survival Analysis. Survivors. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838441.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


73. Lefebvre JL, Lartigau E: Preservation of form and function during management of cancer of the larynx and hypopharynx. World J Surg; 2003 Jul;27(7):811-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preservation of form and function during management of cancer of the larynx and hypopharynx.
  • The treatment of laryngeal and hypopharyngeal cancer has seen notable changes during the twentieth century.
  • Intensive surgical research has allowed laryngologists to deal with almost any local extension and to propose an appropriate surgical procedure for each case.
  • The appearance of platinum-based chemotherapy has updated this discussion.
  • To date, most of the randomized comparisons of mutilating/nonmutilating approaches have been with induction chemotherapy followed by irradiation if there has been a good clinical response to the chemotherapy.
  • There are other options as well that deserve evaluation (e.g., radiotherapy with altered fractionation or with concurrent chemotherapy), although surgery still seems to be indicated in certain cases.
  • Finally, efforts should be made to select patients properly (based on tumor characteristics, clinical aspects, imaging, and biology) for the various strategies with the primary goal of curing the patient and secondarily to preserve laryngeal form and function when possible.
  • [MeSH-major] Hypopharyngeal Neoplasms / therapy. Laryngeal Neoplasms / therapy. Quality of Life
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy / methods. Female. Humans. Laryngectomy / methods. Male. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Recovery of Function. Risk Assessment. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1998 Jun 18;338(25):1798-804 [9632446.001]
  • [Cites] Otolaryngol Head Neck Surg. 1994 Jul;111(1):31-7 [8028939.001]
  • [Cites] Acta Oncol. 1988;27(2):147-52 [3390345.001]
  • [Cites] N Engl J Med. 1992 Oct 15;327(16):1115-21 [1302472.001]
  • [Cites] Radiother Oncol. 1997 Aug;44(2):123-36 [9288840.001]
  • [Cites] Radiother Oncol. 1999 Oct;53(1):15-21 [10624848.001]
  • [Cites] Radiother Oncol. 1991 Mar;20(3):139-48 [1852905.001]
  • [Cites] Radiother Oncol. 1989 Sep;16(1):65-72 [2813838.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(4):725-32 [1618664.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16 [10924966.001]
  • [Cites] J Laryngol Otol. 1993 Mar;107(3):211-6 [8509698.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] Head Neck. 1994 Jan-Feb;16(1):39-44 [7510276.001]
  • [Cites] Oral Oncol. 1998 May;34(3):224-8 [9692058.001]
  • [Cites] Acta Oncol. 1988;27(2):163-7 [3390346.001]
  • [Cites] Laryngoscope. 1997 May;107(5):648-53 [9149168.001]
  • [Cites] Am J Clin Oncol. 1991 Aug;14(4):273-9 [1713738.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):850-9 [2016629.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):83-91 [7819055.001]
  • [Cites] J Laryngol Otol. 1991 Nov;105(11):930-3 [1761947.001]
  • [Cites] Head Neck. 1989 Mar-Apr;11(2):123-8 [2722488.001]
  • [Cites] Laryngoscope. 1995 Aug;105(8 Pt 1):822-6 [7630294.001]
  • (PMID = 14509512.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


74. Duprez F, Madani I, Bonte K, Boterberg T, Vakaet L, Derie C, De Gersem W, De Neve W: Intensity-modulated radiotherapy for recurrent and second primary head and neck cancer in previously irradiated territory. Radiother Oncol; 2009 Dec;93(3):563-9
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiotherapy for recurrent and second primary head and neck cancer in previously irradiated territory.
  • PURPOSE: To evaluate re-irradiation using IMRT for recurrent and second primary head and neck cancer in previously irradiated territory.
  • MATERIALS AND METHODS: Between 1997 and 2008, 84 patients with recurrent and second primary head and neck cancer were treated with IMRT to a median dose of 69 Gy.
  • Median time interval between initial radiotherapy and re-irradiation was 49.5 (5.2-298.3) months.
  • Salvage surgery preceded re-irradiation in 19 patients; 17 patients received concurrent chemotherapy.
  • Stage T4 (p=0.015), time interval between initial treatment and re-irradiation (p=0.011) and hypopharyngeal cancer (p=0.013) were independent prognostic factors for worse overall survival in multivariate analysis.
  • Twenty-six and 11 patients developed Grade 3 acute and late toxicity, respectively.
  • CONCLUSIONS: High-dose IMRT for recurrent and second primary head and neck cancer in previously irradiated territory leads to approximately 20% long-term survival in a non-selected patient population.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasms, Second Primary / radiotherapy. Radiotherapy, Intensity-Modulated

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19919885.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


75. Yamazaki H, Inoue T, Tanaka E, Yoshida K, Imai A, Yoshioka Y, Nakamura H, Yoshida J, Inoue T: Radiation and low dose adriamycin for the treatment of carcinoma of the hypopharynx. Anticancer Res; 2000 Nov-Dec;20(6C):4713-20
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation and low dose adriamycin for the treatment of carcinoma of the hypopharynx.
  • PURPOSE: To evaluate the utility of adriamycin in radiation therapy for hypopharyngeal cancer.
  • PATIENTS AND METHODS: Forty-five patients with hypopharyngeal carcinoma without distant metastasis were treated.
  • /once a week, median 64 mg) concurrently with radiation therapy to 38 patients, 76% (34 out of 45) of whom were in an advanced stage (III or IV).
  • Radiation therapy achieved an 84% (38 out of 45) response rate at 40 Gy.
  • Treatment without voice function loss was attained for 16 patients, consisting of 15 local CR (all T1 and 12 out of 26 T2 tumors) by radical radiation therapy and one posterior wall resection for a T2 tumor.
  • In 18 patients with T2 cancer originating from the pyriform sinus, 69% local control was obtained for patients using adriamycin compared with 20% for patients without adriamycin (p = 0.17).
  • CONCLUSIONS: Radiation therapy using low dose adriamycin with or without follow-up surgery is safe and has potential to be a good option.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Doxorubicin / therapeutic use. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Combined Modality Therapy / adverse effects. Dose-Response Relationship, Radiation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Radiotherapy / adverse effects. Survival Rate. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11205206.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin
  •  go-up   go-down


76. Okada M, Shimono T, Komeya Y, Ando R, Kagawa Y, Katsube T, Kuwabara M, Yagyu Y, Kumano S, Imaoka I, Tsuchiya N, Ashikaga R, Hosono M, Murakami T: Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions. Ann Nucl Med; 2009 Jun;23(4):349-54
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
  • OBJECTIVE: To investigate whether integrated fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) can differentiate benign from adrenal malignant lesions on the basis of maximum standardized uptake value (SUV(max)), tumor/liver (T/L) SUV(max) ratio, and CT attenuation value (Hounsfield Units;.
  • METHODS: We studied 30 patients with 35 adrenal lesions (16 adrenal benign lesions, size 16 +/- 5 mm, in 15 patients; and 19 adrenal malignant lesions, 24 +/- 12 mm, in 15 patients) who had confirmed primary malignancies (lung cancer in 23 patients, lymphoma in 2, esophageal cancer in 2, hypopharyngeal cancer in 1, prostate cancer in 1, and 1 patient in whom lesions were detected at cancer screening).
  • Diagnosis of adrenal malignant lesions was based on interval growth or reduction after chemotherapy.
  • Adrenal uptake of SUV(max) >/= 2.5 was considered to indicate a malignant lesion; SUV(max) < 2.5 was considered to indicate a benign lesion.
  • In further analysis, 1.8 was employed as the threshold for the T/L SUV(max) ratio.
  • Unenhanced CT obtained from PET/CT data was considered positive for adrenal malignant lesions based on a CT attenuation value >/= 10 HU; lesions with a value < 10 HU were considered adrenal benign lesions.
  • RESULTS: SUV(max) in adrenal malignant lesions (7.4 +/- 3.5) was higher than that in adrenal benign lesions (2.1 +/- 0.5, p < 0.05).
  • The CT attenuation value of adrenal malignant lesions (27.6 +/- 11.9 HU) was higher than that of adrenal benign lesions (10.1 +/- 12.3 HU, p < 0.05).
  • In differentiating between adrenal benign and malignant lesions, a CT threshold of 10 HU corresponded to a sensitivity of 57%, specificity of 94%, accuracy of 74%, positive predictive value of 92% and negative predictive value of 65%.
  • The T/L SUV(max) ratio was 1.0 +/- 0.2 for adrenal benign lesions and 4.5 +/- 3.0 for adrenal malignant lesions.
  • CONCLUSIONS: FDG-PET/CT with additional SUV(max) analysis improves the diagnostic accuracy of adrenal lesions in cancer patients.
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Liver / metabolism. Middle Aged. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19340526.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


77. Guntinas-Lichius O, Wendt T, Buentzel J, Esser D, Lochner P, Mueller A, Schultze-Mosgau S, Altendorf-Hofmann A: Head and neck cancer in Germany: a site-specific analysis of survival of the Thuringian cancer registration database. J Cancer Res Clin Oncol; 2010 Jan;136(1):55-63
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Head and neck cancer in Germany: a site-specific analysis of survival of the Thuringian cancer registration database.
  • OBJECTIVE: To describe epidemiology and prognosis of head and neck cancer in Germany.
  • METHODS: We analyzed the Thuringian cancer registry database from 1996 to 2005.
  • 3,821 cases with primary head and neck cancer were evaluated for patient's characteristics, tumor stage, incidence, treatment, and trends in overall survival.
  • RESULTS: During the period 1996-2005, the incidence of oropharynx, hypopharynx, larynx, and salivary gland cancer increased significantly for males, and of oral cavity and hypopharynx cancer for females.
  • There was a significant trend using more multimodal therapy combining surgery, radiotherapy, and chemotherapy, and to use less radiotherapy as a single modality.
  • The median follow-up time of patients alive was 42 months.
  • The site-specific 5-year OS for lip, oral cavity, nasopharynx, oropharynx, hypopharynx, larynx, salivary gland, and nose/paranasal sinus cancer was 75.7, 42.6, 43.5, 45.9, 27.2, 57.3, 61.0, and 34.9%, respectively.
  • The multivariate analysis showed that male gender, age ≥ 60 years, therapy without surgery, higher T classification, N classification, and M classification were independent significant negative risk factors for OS (p < 0.0001).
  • Cancer of the oral cavity and of the hypopharynx had a significant lower OS than lip cancer (p = 0.012 and p = 0.044, respectively).
  • CONCLUSIONS: Many subsites of head and neck cancer have changing incidence.
  • Although treatment strategies have changed, outcome has not improved significantly from 1995 to 2006.
  • [MeSH-major] Databases, Factual / statistics & numerical data. Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / therapy. Registries / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Germany / epidemiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Public Health. 2006 Jun 06;6:146 [16756650.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1143-54 [18784104.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2201-7 [9827726.001]
  • [Cites] Head Neck. 2005 Oct;27(10):843-50 [16161069.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Sep;135(3):451-7 [16949981.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):784-96 [17714993.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):2901-9 [18980273.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Sep;124(9):951-62 [9738803.001]
  • [Cites] Z Gerontol Geriatr. 2005 Feb;38(1):47-59 [15756487.001]
  • [Cites] Mayo Clin Proc. 2008 Apr;83(4):489-501 [18380996.001]
  • [Cites] Semin Oncol. 2008 Jun;35(3):221-8 [18544437.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):581-92 [17287242.001]
  • [Cites] Eur Addict Res. 2003 Oct;9(4):147-56 [12970583.001]
  • [Cites] Laryngorhinootologie. 2002 Jul;81(7):499-508 [12173061.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):806-16 [15609302.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v61-118 [14684501.001]
  • (PMID = 19568769.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


78. Lefebvre JL: Surgery for Laryngopharyngeal SCC in the Era of Organ Preservation. Clin Exp Otorhinolaryngol; 2009 Dec;2(4):159-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This new concept has obviously modified the treatment algorithm for laryngopharyngeal squamous cell carcinoma.
  • However surgery for larynx and hypopharynx cancer remains indicated in many cases.
  • Initial radical surgery is indicated for advanced diseases in case of very infiltrative tumor, in case of cartilage destruction or when tolerance and/or compliance to chemotherapy-based approached is questionable.
  • This discussion underscored the need of a multidisciplinary decision making and the need of a coordinated clinical research.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] Head Neck. 2010 Jan;32(1):1-7 [19953627.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2009 Sep;266(9):1333-52 [19597837.001]
  • [Cites] Strahlenther Onkol. 2009 May;185(5):303-9 [19440669.001]
  • [Cites] J Natl Cancer Inst. 2009 Apr 1;101(7):498-506 [19318632.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1293-303 [19306746.001]
  • [Cites] Head Neck. 2009 Apr;31(4):429-41 [19283793.001]
  • [Cites] Ann Oncol. 2009 May;20(5):921-7 [19179556.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 4;101(3):142-52 [19176454.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3582-9 [18559875.001]
  • [Cites] J Laryngol Otol. 2008 Nov;122(11):1219-23 [18534043.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1997 May;106(5):364-9 [9153099.001]
  • [Cites] Oral Oncol. 1998 May;34(3):224-8 [9692058.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Nov;124(11):1245-50 [9821928.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):877-84 [10673531.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Mar;126(3):285-8 [10721998.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Jan;124(1):58-67 [11228455.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Jan;129(1):44-9 [12525193.001]
  • [Cites] Head Neck. 2003 May;25(5):382-8 [12692875.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2003 Apr;260(4):198-206 [12709803.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Head Neck. 2004 Feb;26(2):163-70 [14762885.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Sep;130(9):1092-9 [15381597.001]
  • [Cites] Head Neck. 2005 Jul;27(7):566-73; discussion 573-4 [15898101.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1368-77 [16169679.001]
  • [Cites] Head Neck. 2006 Jun;28(6):481-6 [16470876.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3693-704 [16832122.001]
  • [Cites] Laryngoscope. 2006 Sep;116(9 Pt 2 Suppl 111):1-13 [16946667.001]
  • [Cites] Lancet. 2006 Sep 2;368(9538):843-54 [16950362.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1198-204 [18086960.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1270-6 [18086971.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):631-40 [18281267.001]
  • (PMID = 20072688.001).
  • [ISSN] 2005-0720
  • [Journal-full-title] Clinical and experimental otorhinolaryngology
  • [ISO-abbreviation] Clin Exp Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2804089
  • [Keywords] NOTNLM ; Hypopharynx / Larynx / Larynx preservation / Squamous cell carcinoma
  •  go-up   go-down


79. Studer G, Lütolf UM, Davis JB, Glanzmann C: IMRT in hypopharyngeal tumors. Strahlenther Onkol; 2006 Jun;182(6):331-5
MedlinePlus Health Information. consumer health - Swallowing Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IMRT in hypopharyngeal tumors.
  • BACKGROUND AND PURPOSE: Intensity-modulated radiation therapy (IMRT) data on hypopharyngeal cancer (HC) are scant.
  • Doses of 60-71 Gy with 2.0-2.2 Gy/fraction were applied.
  • 26/29 patients were definitively irradiated, 86% received simultaneous cisplatin-based chemotherapy.
  • Mean primary tumor volume measured 36.2 cm(3) (4-170 cm(3)), mean nodal volume 16.6 cm(3) (0-97 cm(3)).
  • The mean dose to the spinal cord (extension of > 5-15 mm) was 26 Gy (12-38 Gy); the mean maximum (point) dose was 44.4 Gy (26-58.9 Gy).
  • One grade (G) 3 dysphagia and two G4 reactions (laryngeal fibrosis, dysphagia), both following the schedule with 2.2 Gy per fraction, have been observed so far.
  • In order to avoid G4 reactions, SIB doses of < 2.2 Gy/fraction are recommended for large tumors involving laryngeal structures.
  • [MeSH-major] Deglutition Disorders / etiology. Deglutition Disorders / prevention & control. Hypopharyngeal Neoplasms / radiotherapy. Radiotherapy, Conformal / adverse effects. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Dose Fractionation. Female. Humans. Male. Middle Aged. Radiation Injuries / etiology. Radiation Injuries / prevention & control. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16703288.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


80. Ghaffar S, Akhtar S, Ikram M, Imam SZ, Sepah YJ: Comparison of different treatment modalities in advanced laryngeal hypopharyngeal squamous cell carcinoma. J Coll Physicians Surg Pak; 2010 Mar;20(3):171-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of different treatment modalities in advanced laryngeal hypopharyngeal squamous cell carcinoma.
  • OBJECTIVE: To compare outcome of patients with advanced laryngeal hypopharyngeal squamous cell carcinoma treated surgically or with chemotherapy and/or radiotherapy.
  • METHODOLOGY: Medical records of already treated stage-III and IV squamous cell carcinoma of larynx/hypopharynx patients were reviewed.
  • Group-A comprised of patients treated with surgery +/- adjuvant therapy whereas non-surgically managed patients were labeled as group-B.
  • Kaplan Meier technique was used to estimate mean recurrence time with standard errors.
  • Cox proportional hazard regression was used to estimate the hazard ratio with 95 percent confidence interval for gender, age and tumour location.
  • In group-A, 40% patients received postoperative adjuvant therapy while in group-B, 45% received concomitant chemoradiation.
  • Mean recurrence time was 1369+193 days.
  • In group-A, mean recurrence time was 2097+277 days.
  • The hazard ratio of recurrence in hypopharyngeal tumours was 1.5 times (95% CI 0.68, 3.30) as compared to tumours of larynx.
  • The hazard ratio of recurrence was 1.98 times (95% CI 0.99, 3.95) when both larynx and hypopharynx were involved as compared to when tumour was localized to larynx only.
  • No residual disease was noted at the completion of treatment in surgical group-A while 62% patients of the group-B had residual disease at the completion of treatment.
  • CONCLUSION: Statistically significant difference was noted in disease free outcome when stage-III and IV larynx hypopharynx cancer was managed surgically as compared to non-surgical management.
  • Chances of retaining larynx are only 25% when managed non-surgically.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Hypopharyngeal Neoplasms / therapy. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20392379.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


81. Akisada T, Harada T, Takemoto T, Fukuda K, Morita N, Aihara T, Kajihara Y, Imai S, Gyoten M, Imajo Y, Hiratsuka J: [A case of advanced hypopharyngeal carcinoma successfully treated with superselective intra-arterial infusion of docetaxel]. Gan To Kagaku Ryoho; 2002 Feb;29(2):323-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced hypopharyngeal carcinoma successfully treated with superselective intra-arterial infusion of docetaxel].
  • Docetaxel is an excellent agent with a high antitumor effect for advanced/recurrent head and neck cancer.
  • A 67-year-old male with advanced hypopharyngeal cancer (T3N2bM1: Stage IV) underwent two courses of superselective intra-arterial infusion of docetaxel and intravenous administration of CDDP and 5-FU.
  • During chemotherapy the patient received concomitant radiotherapy (50 Gy).
  • MRI after chemoradiation showed a complete response for the primary tumor and a partial response for the neck metastasis.
  • We conclude that this superselective intra-arterial infusion of docetaxel will be useful and safe for head and neck cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Paclitaxel / administration & dosage. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Male

  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11865643.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


82. Yoon MS, Chung WK, Ahn SJ, Nam TK, Nah BS, Song JY, Lim SC, Lee JK: Concurrent chemoradiotherapy with cisplatin and fluorouracil for locally advanced hypopharyngeal carcinoma. Acta Otolaryngol; 2008 May;128(5):590-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiotherapy with cisplatin and fluorouracil for locally advanced hypopharyngeal carcinoma.
  • CONCLUSIONS: The concurrent administration of cisplatin and fluorouracil (CCRT) during radiotherapy after induction chemotherapy had better results than induction chemotherapy followed by radiotherapy alone (CT+RT) for overall survival, laryngeal preservation, and locoregional control in patients with locally advanced hyopharyngeal cancer.
  • OBJECTIVES: To report treatment results comparing CCRT with CT+RT in locally advanced hypopharyngeal cancer.
  • Thirty-eight patients were treated with induction chemotherapy followed by definitive RT, and 28 patients with induction chemotherapy followed by concurrent chemoradiotherapy.
  • The median dose of irradiation was 70 Gy in the CT+RT group and 68.4 Gy in the CCRT group, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Survival Rate

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18421617.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


83. Garden AS: Organ preservation for carcinoma of the larynx and hypopharynx. Hematol Oncol Clin North Am; 2001 Apr;15(2):243-60, v

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ preservation for carcinoma of the larynx and hypopharynx.
  • Treatment of laryngeal and hypopharyngeal cancers often necessitates total laryngectomy.
  • Strategies include radiation alone, neoadjuvant chemotherapy with radiation for responders, or concurrent chemotherapy and radiation.
  • Both retrospective experiences and randomized trials evaluating differing therapies in an effort to achieve voice preservation are reported and analyzed.
  • [MeSH-major] Laryngeal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11370491.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 81
  •  go-up   go-down


84. Hsiao JR, Leu SF, Huang BM: Apoptotic mechanism of paclitaxel-induced cell death in human head and neck tumor cell lines. J Oral Pathol Med; 2009 Feb;38(2):188-97
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptotic mechanism of paclitaxel-induced cell death in human head and neck tumor cell lines.
  • METHODS: The apoptotic effect and the mechanism of paclitaxel on FaDu hypopharyngeal cancer cell line, OEC-M1 gingival cancer cell line, and OC3 betel quid chewing-related buccal cancer cell lines were investigated by morphological observations, cell viability assay, flow cytometry assay and Western blotting methods.
  • RESULTS: Rounded-up cell number increased with membrane blebbing as the treatment of paclitaxel (50-500 nM) increased from 24 to 48 h among these cell lines.
  • In cell viability assay, cell surviving rate significantly decreased from 87 to 27% as the dosage and duration of paclitaxel treatment increased (P < 0.05).
  • Flow-cytometry analysis further demonstrated that 50 nM paclitaxel induced G2/M phase cell arrest among these cell lines within 8 h treatment, and then G2/M phase cell fraction significantly decreased as subG1 phase cell fraction significantly increased after 24 h treatment (P < 0.05), suggesting that cells underwent apoptosis.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis. Caspases / metabolism. Cell Cycle / drug effects. Paclitaxel / pharmacology
  • [MeSH-minor] Blotting, Western. Carcinoma, Squamous Cell / drug therapy. Cell Line, Tumor / drug effects. Cell Survival / drug effects. Dose-Response Relationship, Drug. Enzyme Activation. Flow Cytometry. Head and Neck Neoplasms / drug therapy. Humans. Poly(ADP-ribose) Polymerases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19200178.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspases; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


85. Walvekar RR, Pantvaidya GH, Desai SB, Chaukar DA, D'Cruz AK: Urinary bladder metastasis--an unusual presentation of distant spread from a primary pyriform sinus cancer: a case report. Auris Nasus Larynx; 2006 Dec;33(4):493-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary bladder metastasis--an unusual presentation of distant spread from a primary pyriform sinus cancer: a case report.
  • Hypopharyngeal cancers have a high propensity to distant metastasis.
  • We present a report of a patient with a treated and controlled pyriform sinus cancer who presented with complaints of dysuria, 8 months after completion of treatment.
  • On further investigation, the patient was found to have disseminated disease for which chemotherapy was instituted.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Hypopharyngeal Neoplasms / pathology. Urinary Bladder Neoplasms / secondary

  • Genetic Alliance. consumer health - Sinus cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16920307.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


86. Oueslati Z, Ben Miled M, Hammoud M, Touati S, Lachkham A, Gamoudi A, Mokni N, El Benna F, Boussen H, El May A, Ladgham A: [Sarcomatoid carcinomas of the upper airways]. Rev Laryngol Otol Rhinol (Bord); 2008;129(3):191-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Carcinomes sarcomatoïdes des voies aéro-digestives supérieures.
  • INTRODUCTION: The sarcomatoid carcinoma of the superior aerodigestive tracts is a rare malignant tumour which presents diagnostic and therapeutic challenges.
  • Tumoral locations were as follows: larynx: 6, hypopharynx: 1, oropharynx: 1, nasopharynx: 1, oral cavity: 2.
  • Histological diagnosis in 3 cases required the use of immunohistochemical studies.
  • This left 9 patients and among them 7 received a curative treatment: 5 by surgery alone, 1 by surgery and radiotherapy, 1 by radiotherapy, 1 by chemo-radiotherapy for the nasopharyngeal lesion and 1 by chemotherapy alone.
  • Two patients died from their disease before treatment.
  • Its diagnosis benefits from progresses in immunohistochemistry, but also from advances in the field of molecular biology.
  • Its treatment and natural evolution remain controversial.
  • [MeSH-major] Carcinoma / diagnosis. Otorhinolaryngologic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Radiation-Induced / mortality. Neoplasms, Radiation-Induced / pathology. Neoplasms, Radiation-Induced / therapy. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / therapy. Retrospective Studies. Smoking / adverse effects. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694162.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


87. Zackrisson B, Mercke C, Strander H, Wennerberg J, Cavallin-Ståhl E: A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol; 2003;42(5-6):443-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic overview of radiation therapy effects in head and neck cancer.
  • A systematic review of radiation therapy trials in several tumour types was performed by The Swedish Council of Technology Assessment in Health Care (SBU).
  • This synthesis of the literature on radiation therapy for head and neck cancer is based on data from 39 randomized trials and 1 meta-analysis.
  • The conclusions reached can be summarized as follows: General, non-nasopharynx.
  • Substantial evidence indicates that the tumour effect of radiotherapy can be increased by the concomitant administration of chemotherapeutic agents, particularly cisplatin and 5-fluorouracil.
  • There is moderate evidence of a survival benefit of radiation combined with concomitant chemotherapy compared to radiation alone.
  • There is substantial evidence in published studies for an increased frequency of severe acute side effects as a result of concomitant chemotherapy and radiotherapy.
  • There is strong evidence that larynx preservation is possible in 50% of the patients surviving for 5 years with hypopharyngeal cancers when treated with neoadjuvant chemotherapy and radical radiotherapy There is a non-significant trend for the overall survival being lower in non-surgically treated patients than in those treated with primary surgery and postoperative radiotherapy Nasopharynx.
  • There is moderate evidence that patients with nasopharyngeal carcinomas of the endemic type benefit from therapy with a combination of chemotherapy and radical radiotherapy.
  • There is some evidence that certain schedules of altered fractionation improve tumour control without increasing severe late side effects.
  • There is some evidence that nervous tissues are more susceptible to damage by altered fractionation.
  • There is moderate evidence that accelerated hyperfractionation may reduce the frequency of serious late side effects while retaining a similar tumour effect as conventional radiotherapy Hypoxic cell sensitizers.
  • Most reported trials reject the usefulness of nitroimidazole derivatives for sensitization of hypoxic tumour cells.
  • There is some evidence that patients with tumours in the pharynx and larynx may benefit from sensitization by nimorazole.
  • Prophylactic treatment of side effects.
  • There is insufficient evidence that radioprotective agents do not spare tumour tissue.
  • Both methods are well established and have independently proved to be effective in the treatment of certain head and neck cancers.
  • [MeSH-minor] Adult. Aged. Dose Fractionation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiation Injuries. Radiotherapy Dosage. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Risk Assessment. Survival Analysis. Sweden. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14596506.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 43
  •  go-up   go-down


88. Tian WD, Zeng ZY, Yu WB, Li XP: [Application of SELDI-TOF-MS in establishing a model for predicting radiotherapy response of hypopharyngeal cancers]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun;30(6):1282-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of SELDI-TOF-MS in establishing a model for predicting radiotherapy response of hypopharyngeal cancers].
  • OBJECTIVE: To detect the serum proteomic fingerprints in patients with hypopharyngeal squamous cell carcinoma (HPSCC) by surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) protein chip array technique.
  • RESULTS: The protein profiles of HPSCC serum were analyzed according to the clinical and pathological features of the patients and their treatment response.
  • No significant difference was found in the serum proteins between chemotherapy-sensitive patients and the insensitive patients (P>0.05), but 5 proteins were identified to be overexpressed in the sensitive patients (P < / = 0.05).
  • CONCLUSION: The serum protein at the m/z value of 6115.74 is overexpressed in radiotherapy-sensitive HPSCC patients.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / radiotherapy. Proteome / analysis. Radiation Tolerance. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Male. Middle Aged. Models, Biological. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20584658.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome
  •  go-up   go-down


89. Gupta T, Chopra S, Agarwal JP, Laskar SG, D'cruz AK, Shrivastava SK, Dinshaw KA: Squamous cell carcinoma of the hypopharynx: single-institution outcome analysis of a large cohort of patients treated with primary non-surgical approaches. Acta Oncol; 2009;48(4):541-48
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the hypopharynx: single-institution outcome analysis of a large cohort of patients treated with primary non-surgical approaches.
  • INTRODUCTION: Hypopharyngeal cancers have extensive submucosal spread, high risk of nodal involvement and relatively high propensity of distant metastases.
  • Contemporary paradigms for hypopharyngeal cancers aim to maximize loco-regional control while attempting to preserve laryngo-pharyngeal form and function.
  • AIMS: To retrospectively review outcome of large cohort of patients with hypopharyngeal cancers treated with curative intent radiotherapy with or without systemic chemotherapy in an academic tertiary referral centre.
  • MATERIAL AND METHODS: Medical records of patients with hypopharyngeal cancers treated with primary non-surgical approaches over a 15-year period were reviewed retrospectively.
  • RESULTS: Electronic search of database identified 501 patients with hypopharyngeal cancers treated with definitive radiotherapy.
  • The median age was 55 years (range 20-87 years) and median radiotherapy dose 70 Gy (range 5.4-72 Gy).
  • CONCLUSION: This is an outcome analysis of the largest cohort of patients with hypopharyngeal cancers managed with primary non-surgical approaches.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Analysis of Variance. Chemotherapy, Adjuvant / adverse effects. Cohort Studies. Disease-Free Survival. Female. Humans. Male. Medical Records. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Retrospective Studies. Risk Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18979267.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


90. Artico R, Bison E, Brotto M: Monophasic synovial sarcoma of hypopharynx: case report and review of the literature. Acta Otorhinolaryngol Ital; 2004 Feb;24(1):33-6
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monophasic synovial sarcoma of hypopharynx: case report and review of the literature.
  • Synovial sarcoma (SS) is a malignant mesenchymal neoplasm usually involving the lower limbs of young adults.
  • Immunohistochemistry plays a crucial role in the diagnosis.
  • Treatment options include an aggressive surgical approach and radiotherapy, whereas the role of chemotherapy remains to be defined.
  • The case is described of monophasic synovial sarcoma located in the hypopharynx and a review is made of the literature concerning this rare neoplasm.
  • [MeSH-major] Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / radiography. Sarcoma, Synovial / pathology. Sarcoma, Synovial / radiography
  • [MeSH-minor] Adult. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15270432.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 22
  •  go-up   go-down


91. Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R, Head and Neck Cancer Disease Site Group: Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol; 2010 Jun;17(3):37-48
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
  • QUESTION: What are the benefits associated with the use of anti-epidermal growth factor receptor (anti-EGFR) therapies in squamous cell carcinoma of the head and neck (HNSCC)?
  • Anti-EGFR therapies of interest included cetuximab, gefitinib, lapatinib, zalutumumab, erlotinib, and panitumumab.
  • PERSPECTIVES: Head-and-neck cancer includes malignant tumours arising from a variety of sites in the upper aerodigestive tract.
  • The most common histologic type is squamous cell carcinoma, and most common sites are the oral cavity, the oropharynx, the hypopharynx, and the larynx.
  • Worldwide, HNSCC is the sixth most common neoplasm, and despite advances in therapy, long-term survival in HNSCC patients is poor.
  • Primary surgery followed by chemoradiation, or primary chemoradiation, are the standard treatment options for patients with locally advanced (stages III-IVB) HNSCC; however, meta-analytic data indicate that the benefit of concurrent platinum-based chemotherapy disappears in patients over the age of 70 years.
  • Cetuximab is a monoclonal antibody approved for use in combination with radiation in the treatment of patients with untreated locally advanced HNSCC and as monotherapy for patients with recurrent or metastatic (stage IVC) HNSCC who have progressed on platinum-based therapy.
  • Given the interest in anti-EGFR agents in advanced HNSCC, the Head and Neck Cancer Disease Site Group (DSG) of Cancer Care Ontario's Program in Evidence-Based Care (PEBC) chose to systematically review the literature pertaining to this topic so as to develop evidence-based recommendations for treatment.
  • OUTCOMES: Outcomes of interest included overall and progression-free survival, quality of life, tumour response rate and duration, and the toxicity associated with the use of anti-EGFR therapies.
  • The resulting recommendations were approved by the Report Approval Panel of the PEBC, and by the Head and Neck Cancer DSG.
  • The randomized controlled trials (RCTS) involved three distinct patient populations: those with locally advanced HNSCC being treated for cure, those with incurable advanced recurrent or metastatic HNSCC being treated with first-line platinum-based chemotherapy, and those with incurable advanced recurrent or metastatic HNSCC who had disease progression despite, or who were unsuitable for, first-line platinum-based chemotherapy.
  • Platinum-based chemoradiation remains the current standard of care for treatment of locally advanced HNSCC.
  • In patients with locally advanced HNSCC who are medically unsuitable for concurrent platinum based chemotherapy or who are over the age of 70 years (because concurrent chemotherapy does not appear to improve overall survival in this patient population), the addition of cetuximab to radical radiotherapy should be considered to improve overall survival, progression-free survival, and time to local recurrence.Cetuximab in combination with platinum-based combination chemotherapy is superior to chemotherapy alone in patients with recurrent or metastatic HNSCC, and is recommended to improve overall survival, progression-free survival, and response rate.The role of anti-EGFR therapies in the treatment of locally advanced HNSCC is currently under study in large randomized trials, and patients with HNSCC should continue to be offered clinical trials of novel agents aimed at improving outcomes.
  • However, five ongoing trials are investigating the effect of the addition of EGFR inhibitors concurrently with, before, or after chemoradiotherapy; those trials should provide direction about the best integration of cetuximab into standard treatment.
  • In patients with recurrent or metastatic HNSCC who experience progressive disease despite, or who are unsuitable for, first-line platinum-based chemotherapy, gefitinib at doses of 250 mg or 500 mg daily, compared with weekly methotrexate, did not increase median overall survival [hazard ratio (hr): 1.22; 96% confidence interval (ci): 0.95 to 1.57; p = 0.12 (for 250 mg daily vs. weekly methotrexate); hr: 1.12; 95% ci: 0.87 to 1.43; p = 0.39 (for 500 mg daily vs. weekly methotrexate)] or objective response rate (2.7% for 250 mg and 7.6% for 500 mg daily vs. 3.9% for weekly methotrexate, p > 0.05).
  • As compared with methotrexate, gefitinib was associated with an increased incidence of tumour hemorrhage (8.9% for 250 mg and 11.4% for 500 mg daily vs. 1.9% for weekly methotrexate).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1995 Jul;72(1):123-8 [7599040.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1757-65 [18946061.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1226-31 [9508211.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1796-807 [10974628.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1523-32 [11410486.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5 Suppl 14):18-30 [12422310.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):555-9 [12566295.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):246-54 [12909240.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 6:vi20-vi24 [15987992.001]
  • [Cites] Expert Opin Biol Ther. 2005 Aug;5(8):1085-93 [16050785.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8646-54 [16314626.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2659-65 [16763280.001]
  • [Cites] Cancer Biol Ther. 2006 Apr;5(4):340-2 [16808060.001]
  • [Cites] J Dent Res. 2007 Feb;86(2):104-14 [17251508.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2191-7 [17538164.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S112-4 [17848275.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):407-20 [18334711.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1116-27 [18784101.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]
  • (PMID = 20567625.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2880902
  • [Keywords] NOTNLM ; Head-and-neck cancer / egfr inhibitors / epidermal growth factor receptor / overall survival / progression-free survival / tumour response rate
  •  go-up   go-down


92. Agarwal J, Dutta D, Palwe V, Gupta T, Laskar SG, Budrukkar A, Murthy V, Chaturvedi P, Pai P, Chaukar D, D'Cruz AK, Kulkarni S, Kulkarni A, Baccher G, Shrivastava SK: Prospective subjective evaluation of swallowing function and dietary pattern in head and neck cancers treated with concomitant chemo-radiation. J Cancer Res Ther; 2010 Jan-Mar;6(1):15-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective subjective evaluation of swallowing function and dietary pattern in head and neck cancers treated with concomitant chemo-radiation.
  • AIM: Prospective subjective evaluation of swallowing function and dietary pattern in locally advanced head and neck cancer patients treated with concomitant chemo-radiotherapy (CRT).
  • MATERIALS AND METHODS: Prospective evaluation of swallowing function with performance status scale for head and neck cancer patients (PSSHN) at pre-CRT, CRT completion and at subsequent follow-ups in adult with loco-regionally advanced head and neck squamous cell carcinoma (HNSCC) patients.
  • RESULTS: In 47 patients (40 male, seven females; mean age 53; 72% smoker 53%, oropharyngeal cancer), the mean total PSSHN score at pre-CRT was 258.5 and decreased to 225.2 and 219.2 at two and six months respectively.
  • In univariate analysis, pre-CRT PSSHN scores were significantly lesser in patients with severe pre-CRT dysphagia (P = 0.001), hypopharyngeal cancer (P = 0.244) and advanced T-stage (T3/4) disease (P = 0.144).
  • Mean increase in meal time was 13% and 21% at two and six-month follow-up.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Deglutition Disorders / epidemiology. Diet. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Deglutition / drug effects. Deglutition / radiation effects. Developing Countries. Female. Humans. India. Male. Middle Aged. Radiotherapy / adverse effects. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479541.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


93. Varghese BT, Sebastian P, Mathew A: Treatment outcome in patients undergoing surgery for carcinoma larynx and hypopharynx: a follow-up study. Acta Otolaryngol; 2009 Dec;129(12):1480-5
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome in patients undergoing surgery for carcinoma larynx and hypopharynx: a follow-up study.
  • CONCLUSIONS: Compared with larynx cancers salvage rates are poorer for hypopharyngeal cancers and the role of primary surgery seems to be significantly higher and more decisive in overall survival (OS).
  • Hypopharyngeal cancers therefore warrant a closer follow-up after an organ preservation protocol, to detect recurrence at the earliest stage and plan for an effective salvage surgery.
  • OBJECTIVE: To evaluate the survival and morbidity of patients treated by surgery for carcinoma of the larynx and hypopharynx according to site.
  • PATIENTS AND METHODS: All patients who had undergone laryngectomy at the Division of Surgical Oncology Regional Cancer Center (RCC) from June 1995 to December 2005 were included in the study, which retrospectively recorded the age and sex distribution, TNM stage, indication, type of laryngectomy and reconstructive option used.
  • The therapeutic outcome, disease-free survival (DFS), OS, voice preservation and postoperative voice rehabilitation were analysed.
  • RESULTS: Of a total of 167 cases, 123 (74%) had salvage surgery for failed chemoradiotherapy/radical radiotherapy and 44 (26%) had primary surgical treatment.
  • Five patients received platinum-based neoadjuvant chemotherapy and nine had postoperative chemotherapy.
  • There was a statistically significant survival difference between salvage and primary surgical cases among cancers of the larynx and hypopharynx.
  • Hypopharyngeal salvage rate was significantly lower in the present study.
  • Fifty-six (34%) patients recurred locoregionally, 4 (2.3%) patients developed a second primary and 5 (2.9%) had distant metastasis.
  • Seventeen patients had voice prosthesis insertion (6 primary and 10 secondary), 3 patients developed good oesophageal speech and voice preservation was possible in 18 patients.
  • Seventy-nine patients were alive at the time of completing the study.
  • [MeSH-major] Carcinoma / surgery. Hypopharyngeal Neoplasms / surgery. Laryngeal Neoplasms / surgery. Laryngectomy. Postoperative Complications / epidemiology
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. India / epidemiology. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19922101.001).
  • [ISSN] 1651-2251
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


94. Mikić A, Pendjer I, Dudvarski Z, Trivić A, Hirurgiju M: [Analyses of the results in the treatment of locally advanced hypopharyngeal carcinoma with different therapeutic approach]. Acta Chir Iugosl; 2009;56(1):35-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analyses of the results in the treatment of locally advanced hypopharyngeal carcinoma with different therapeutic approach].
  • INTRODUCTION: treatment of locoregional advanced hypopharyngeal cancers of grades III and IV would be surgery and/or radiotherapy.
  • An increasing number of authors has emphasized favorable effects of neoadjuvant chemotherapy and radiotherapy with potentiation.
  • THE AIM: the authors presented therapeutical results of three-year survived patients with squamocellular cancers of the hypopharynx (SCC Hy), grades III and IV, in relation to specific modalities of therapeutical approach.
  • Group II included 16 patients who underwent induction chemotherapy, surgery and postoperative radiotherapy (IC-SUR-RT).
  • Group IV involved 29 patients who were treated, in the period 2003-2006, by neoadjuvant chemotherapy followed by radiotherapy with potentiation (CHT-RT).
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Hypopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19504987.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down






Advertisement